N-PX 1 tm2023929d1_npx.htm N-PX
Field: Rule-Page
Field: /Rule-Page
| UNITED
STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 |
| --- |
| OMB Number: 3235-0582 |
| Expires: May 31, 2021 |
| Estimated average burden |
| hours per response........7.2 |
FORM N-PX
ANNUAL REPORT OF PROXY VOTING RECORD OF REGISTERED MANAGEMENT INVESTMENT COMPANY
Investment Company Act file number 811- 04889
Tekla Healthcare Investors
(Exact name of registrant as specified in charter)
| 100
Federal Street, 19 th Floor, Boston, MA | 02110 |
| --- | --- |
| (Address
of principal executive offices) | (Zip
code) |
Laura Woodward
Tekla Healthcare Investors
100 Federal Street, 19 th Floor, Boston MA 02110
(Name and address of agent for service)
Registrant’s telephone number, including area code: 617-772-8500
Date of fiscal year end: September 30
Date of reporting period: 7/1/19-6/30/20
Form N-PX is to be used by a registered management investment company, other than a small business investment company registered on Form N-5 (ss.ss. 239.24 and 274.5 of this chapter), to file reports with the Commission, not later than August 31 of each year, containing the registrant’s proxy voting record for the most recent twelve-month period ended June 30, pursuant to section 30 of the Investment Company Act of 1940 and rule 30b1-4 thereunder (17 CFR 270.30b1-4). The Commission may use the information provided on Form N-PX in its regulatory, disclosure review, inspection, and policymaking roles.
A registrant is required to disclose the information specified by Form N-PX, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-PX unless the Form displays a currently valid Office of Management and Budget (“OMB”) control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. ss. 3507.
Field: Rule-Page
Field: /Rule-Page
Field: Page; Sequence: 1
Field: /Page
Item 1. Proxy Voting Record.
Field: Page; Sequence: 2
Field: /Page
HQH Vote Summary
ABBVIE INC.
| Security |
00287Y109 |
Meeting Type |
Annual |
| Ticker Symbol |
ABBV |
Meeting Date |
08-May-2020 |
| Record Date |
13-Mar-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Robert J. Alpern |
For |
For |
|
2 |
Edward M. Liddy |
For |
For |
|
3 |
Melody B. Meyer |
For |
For |
|
4 |
Frederick H. Waddell |
For |
For |
| 2. |
Ratification of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2020 |
Management |
For |
For |
| 3. |
Say on Pay - An advisory vote on the approval of executive compensation |
Management |
For |
For |
| 4. |
Approval of a management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting |
Management |
For |
For |
| 5. |
Stockholder Proposal - to Issue an Annual Report on Lobbying |
Shareholder |
Against |
For |
| 6. |
Stockholder Proposal - to Adopt a Policy to Require Independent Chairman |
Shareholder |
For |
Against |
| 7. |
Stockholder Proposal - to Issue a Compensation Committee Report on Drug Pricing |
Shareholder |
Against |
For |
ABIOMED, INC.
| Security |
003654100 |
Meeting Type |
Annual |
| Ticker Symbol |
ABMD |
Meeting Date |
07-Aug-2019 |
| Record Date |
10-Jun-2019 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Michael R. Minogue |
For |
For |
|
2 |
Martin P. Sutter |
For |
For |
| 2. |
Approval, by non-binding advisory vote, of the compensation of our named executive officers. |
Management |
For |
For |
| 3. |
Ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2020. |
Management |
For |
For |
AC IMMUNE SA
| Security |
H00263105 |
Meeting Type |
Annual |
| Ticker Symbol |
ACIU |
Meeting Date |
26-Jun-2020 |
| Record Date |
18-May-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1 |
Approval of the Annual Report, Annual Statutory Financial Statements and Financial Statements under IFRS for the Year 2019 |
Management |
For |
For |
| 2 |
Appropriation of Profit |
Management |
For |
For |
| 3 |
Discharge of the Members of the Board of Directors and of the Executive Committee |
Management |
For |
For |
| 4A |
Binding vote on Total Non-Performance-Related Compensation for Members of the Board of Directors from 1 July 2020 to 30 June 2021 |
Management |
For |
For |
| 4B |
Binding vote on Equity for Members of the Board of Directors from 1 July 2020 to 30 June 2021 |
Management |
For |
For |
| 4C |
Binding vote on Total Non-Performance-Related Compensation for Members of the Executive Committee from 1 July 2020 to 30 June 2021 |
Management |
For |
For |
| 4D |
Binding vote on Total Variable Compensation for Members of the Executive Committee for the current year 2020 |
Management |
For |
For |
| 4E |
Binding vote on Equity for Members of the Executive Committee from 1 July 2020 to 30 June 2021 |
Management |
For |
For |
| 4F |
Advisory vote on the 2019 Compensation Report |
Management |
For |
For |
| 5AA |
Re-election to the Board of Director: Douglas Williams as member and Chairman |
Management |
For |
For |
| 5AB |
Re-election to the Board of Director: Martin Velasco as member and Vice-Chairman |
Management |
For |
For |
| 5AC |
Re-election to the Board of Director: Peter Bollmann |
Management |
For |
For |
| 5AD |
Re-election to the Board of Director: Andrea Pfeifer |
Management |
For |
For |
| 5AE |
Re-election to the Board of Director: Tom Graney |
Management |
For |
For |
| 5AF |
Re-election to the Board of Director: Werner Lanthaler |
Management |
For |
For |
| 5AG |
Re-election to the Board of Director: Roy Twyman |
Management |
For |
For |
| 5BA |
Re-election of the Member of the Compensation, Nomination & Corporate Governance Committee: Douglas Williams |
Management |
For |
For |
| 5BB |
Re-election |
|
|
|
| of the Member of the Compensation, Nomination & Corporate |
|
|
|
|
| Governance Committee: Martin Velasco |
Management |
For |
For |
|
| 5BC |
Re-election of the Member of the Compensation, Nomination & Corporate Governance Committee: Tom Graney |
Management |
For |
For |
| 5C |
Re-election of PricewaterhouseCoopers SA (Pully) as statutory auditors |
Management |
For |
For |
| 5D |
Re-election of Reymond & Associés (Lausanne) as independent proxy |
Management |
For |
For |
| 6A |
Amendments to the Articles of Association: Authorized Share Capital |
Management |
For |
For |
| 6B |
Amendments to the Articles of Association: Conditional Capital Increase for Bonds and Similar Debt Instruments |
Management |
For |
For |
| A. |
If a new agenda item or a new proposal for an existing agenda item is put before the meeting, I/we hereby authorize and instruct the independent proxy to vote as follows: |
Management |
For |
|
Field: Page; Sequence: 3
Field: /Page
ACADIA HEALTHCARE COMPANY, INC.
| Security |
00404A109 |
Meeting Type |
Annual |
| Ticker Symbol |
ACHC |
Meeting Date |
07-May-2020 |
| Record Date |
12-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Wade D. Miquelon |
Management |
For |
For |
| 1B. |
Election of Director: William M. Petrie, M.D. |
Management |
For |
For |
| 2. |
Advisory vote on the compensation of the Company's named executive officers as presented in the Proxy Statement. |
Management |
For |
For |
| 3. |
Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
ACADIA PHARMACEUTICALS INC.
| Security |
004225108 |
Meeting Type |
Annual |
| Ticker Symbol |
ACAD |
Meeting Date |
23-Jun-2020 |
| Record Date |
24-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
James M. Daly |
For |
For |
|
2 |
Edmund P. Harrigan, M.D |
For |
For |
| 2. |
To approve an amendment to our 2004 Employee Stock Purchase Plan to increase the aggregate number of shares of common stock authorized for issuance thereunder by 3,000,000 shares. |
Management |
For |
For |
| 3. |
To approve our non-employee director compensation policy. |
Management |
For |
For |
| 4. |
To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement for the annual meeting. |
Management |
For |
For |
| 5. |
To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
ACCELERON PHARMA INC.
| Security |
00434H108 |
Meeting Type |
Annual |
| Ticker Symbol |
XLRN |
Meeting Date |
04-Jun-2020 |
| Record Date |
07-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Class I Director: Thomas A. McCourt |
Management |
For |
For |
| 1B. |
Election of Class I Director: Francois Nader, M.D. |
Management |
For |
For |
| 2. |
To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the proxy statement. |
Management |
For |
For |
| 3. |
To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
Field: Page; Sequence: 4
Field: /Page
AERIE PHARMACEUTICALS, INC.
| Security |
00771V108 |
Meeting Type |
Annual |
| Ticker Symbol |
AERI |
Meeting Date |
11-Jun-2020 |
| Record Date |
14-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
V. Anido, Jr., Ph.D. |
For |
For |
|
2 |
B. McGraw, III, Pharm.D |
For |
For |
|
3 |
J. McHugh |
For |
For |
| 2. |
Ratification |
|
|
|
| of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
|
| 3. |
To approve, by a non-binding vote, the compensation of our named executive officers ("say-on-pay"). |
Management |
For |
For |
AERPIO PHARMACEUTICALS, INC.
| Security |
00810B105 |
Meeting Type |
Annual |
| Ticker Symbol |
ARPO |
Meeting Date |
24-Jun-2020 |
| Record Date |
27-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Joseph Gardner |
For |
For |
|
2 |
Steven Prelack |
For |
For |
| 2. |
To approve a potential amendment to our Amended and Restated Certificate of Incorporation to effect a Reverse Stock Split of the Common Stock at a ratio within the range of 1-for-15 to 1-for-25, such ratio to be determined in the sole discretion of the Board of Directors. |
Management |
For |
For |
| 3. |
To ratify the appointment of Ernst & Young LLP as Aerpio's independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
AGIOS PHARMACEUTICALS, INC.
| Security |
00847X104 |
Meeting Type |
Annual |
| Ticker Symbol |
AGIO |
Meeting Date |
28-May-2020 |
| Record Date |
07-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Paul J. Clancy |
For |
For |
|
2 |
Ian T. Clark |
For |
For |
| 2. |
To vote, on an advisory basis, to approve named executive officer compensation. |
Management |
For |
For |
| 3. |
To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
ALEXION PHARMACEUTICALS, INC.
| Security |
015351109 |
Meeting Type |
Annual |
| Ticker Symbol |
ALXN |
Meeting Date |
13-May-2020 |
| Record Date |
16-Mar-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Felix J. Baker |
For |
For |
|
2 |
David R. Brennan |
For |
For |
|
3 |
Christopher J. Coughlin |
For |
For |
|
4 |
Deborah Dunsire |
For |
For |
|
5 |
Paul A. Friedman |
For |
For |
|
6 |
Ludwig N. Hantson |
For |
For |
|
7 |
John T. Mollen |
For |
For |
|
8 |
Francois Nader |
For |
For |
|
9 |
Judith A. Reinsdorf |
For |
For |
|
10 |
Andreas Rummelt |
For |
For |
| 2. |
Proposal No. 2 - Ratification of appointment by the Board of Directors of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm. |
Management |
For |
For |
| 3. |
Proposal No. 3 - Approval of a non-binding advisory vote of the 2019 compensation paid to Alexion's named executive officers. |
Management |
For |
For |
| 4. |
Proposal No. 4 - Shareholder proposal requesting certain By-law amendments to lower the threshold for shareholders to call a special meeting. |
Shareholder |
Against |
For |
Field: Page; Sequence: 5
Field: /Page
ALIGN TECHNOLOGY, INC.
| Security |
016255101 |
Meeting Type |
Annual |
| Ticker Symbol |
ALGN |
Meeting Date |
20-May-2020 |
| Record Date |
25-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Kevin J. Dallas |
Management |
For |
For |
| 1B. |
Election of Director: Joseph M. Hogan |
Management |
For |
For |
| 1C. |
Election of Director: Joseph Lacob |
Management |
For |
For |
| 1D. |
Election of Director: C. Raymond Larkin, Jr. |
Management |
For |
For |
| 1E. |
Election of Director: George J. Morrow |
Management |
For |
For |
| 1F. |
Election of Director: Anne M. Myong |
Management |
For |
For |
| 1G. |
Election of Director: Thomas M. Prescott |
Management |
For |
For |
| 1H. |
Election of Director: Andrea L. Saia |
Management |
For |
For |
| 1I. |
Election of Director: Greg J. Santora |
Management |
For |
For |
| 1J. |
Election of Director: Susan E. Siegel |
Management |
For |
For |
| 1K. |
Election of Director: Warren S. Thaler |
Management |
For |
For |
| 2. |
RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS: Proposal to ratify the appointment of PricewaterhouseCoopers LLP as Align Technology, Inc.'s independent registered public accountants for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 3. |
ADVISORY VOTE TO APPROVE NAMED EXECUTIVE OFFICER COMPENSATION. |
Management |
For |
For |
ALKERMES PLC
| Security |
G01767105 |
Meeting Type |
Annual |
| Ticker Symbol |
ALKS |
Meeting Date |
20-May-2020 |
| Record Date |
17-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1.1 |
Election of Class III Director to serve for a three-year term: Shane M. Cooke |
Management |
For |
For |
| 1.2 |
Election of Class III Director to serve for a three-year term: Richard B. Gaynor, M.D. |
Management |
For |
For |
| 1.3 |
Election of Class III Director to serve for a three-year term: Paul J. Mitchell |
Management |
For |
For |
| 1.4 |
Election of Class III Director to serve for a three-year term: Richard F. Pops |
Management |
For |
For |
| 2. |
To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers. |
Management |
For |
For |
| 3. |
To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company and to authorize, in a binding vote, the Audit and Risk Committee of the Company's Board of Directors (the Board) to set the independent auditor and accounting firm's remuneration. |
Management |
For |
For |
| 4. |
To approve the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. |
Management |
For |
For |
ALLAKOS INC.
| Security |
01671P100 |
Meeting Type |
Annual |
| Ticker Symbol |
ALLK |
Meeting Date |
26-May-2020 |
| Record Date |
09-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
John McKearn, Ph.D. |
For |
For |
|
2 |
Paul Walker |
For |
For |
| 2. |
Ratification and approval of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 3. |
Approval, on an advisory non-binding basis, the frequency of future advisory votes to approve the compensation of our named executive officers. |
Management |
1 Year |
Against |
Field: Page; Sequence: 6
Field: /Page
ALLERGAN PLC
| Security |
G0177J108 |
Meeting Type |
Special |
| Ticker Symbol |
AGN |
Meeting Date |
14-Oct-2019 |
| Record Date |
16-Sep-2019 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
COURT MEETING: Approve the scheme of arrangement. |
Management |
For |
For |
| 2. |
Extraordinary General Meeting: Approve the scheme of arrangement and authorize the directors of Allergan plc to take all such actions as they consider necessary or appropriate for carrying the scheme of arrangement into effect. |
Management |
For |
For |
| 3. |
Extraordinary General Meeting: Approve the cancellation of any Allergan plc ordinary shares in issue at 11:59 p.m., Irish time, on the day before the Irish High Court hearing to sanction the scheme (excluding, in any case, any Allergan plc ordinary shares which are held from time to time by AbbVie Inc., Acquirer Sub (as defined in the scheme of arrangement) or any other subsidiary of AbbVie Inc., if any). |
Management |
For |
For |
| 4. |
Extraordinary General Meeting: Authorize the directors of Allergan plc to allot and issue new Allergan plc shares, fully paid up, to Acquirer Sub and/or its nominee(s) in connection with effecting the scheme. |
Management |
For |
For |
| 5. |
Extraordinary General Meeting: Amend the articles of association of Allergan plc so that any ordinary shares of Allergan plc that are issued on or after the Voting Record Time (as defined in the scheme of arrangement) to persons other than Acquirer Sub or its nominees will either be subject to the terms of the scheme or will be immediately and automatically acquired by Acquirer Sub and/or its nominee(s) for the scheme consideration. |
Management |
For |
For |
| 6. |
Extraordinary General Meeting: Approve, on a non- binding, advisory basis, specified compensatory arrangements between Allergan plc and its named executive officers relating to the transaction. |
Management |
For |
For |
| 7. |
Extraordinary General Meeting: Approve any motion by the Chairman to adjourn the extraordinary general meeting, or any adjournments thereof, to solicit additional proxies in favor of the approval of the resolutions if there are insufficient votes at the time of the extraordinary general meeting to approve resolutions 2 through 5. |
Management |
For |
For |
ALLOGENE THERAPEUTICS, INC.
| Security |
019770106 |
Meeting Type |
Annual |
| Ticker Symbol |
ALLO |
Meeting Date |
05-Jun-2020 |
| Record Date |
21-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Deborah Messemer |
Management |
For |
For |
| 1B. |
Election of Director: Todd Sisitsky |
Management |
For |
For |
| 1C. |
Election of Director: Owen Witte, M.D. |
Management |
For |
For |
| 2. |
To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers. |
Management |
1 Year |
For |
| 3. |
To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020. |
Management |
For |
For |
Field: Page; Sequence: 7
Field: /Page
ALNYLAM PHARMACEUTICALS, INC.
| Security |
02043Q107 |
Meeting Type |
Annual |
| Ticker Symbol |
ALNY |
Meeting Date |
06-May-2020 |
| Record Date |
09-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Class I Director: Michael W. Bonney |
Management |
For |
For |
| 1B. |
Election of Class I Director: John M. Maraganore, Ph.D. |
Management |
For |
For |
| 1C. |
Election of Class I Director: Phillip A. Sharp, Ph.D. |
Management |
For |
For |
| 2. |
To approve an Amendment to our 2018 Stock Incentive Plan, as amended. |
Management |
For |
For |
| 3. |
To approve an Amendment to our Amended and Restated 2004 Employee Stock Purchase Plan, as amended. |
Management |
For |
For |
| 4. |
To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers. |
Management |
For |
For |
| 5. |
To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2020. |
Management |
For |
For |
AMERISOURCEBERGEN CORPORATION
| Security |
03073E105 |
Meeting Type |
Annual |
| Ticker Symbol |
ABC |
Meeting Date |
05-Mar-2020 |
| Record Date |
06-Jan-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Ornella Barra |
Management |
For |
For |
| 1B. |
Election of Director: Steven H. Collis |
Management |
For |
For |
| 1C. |
Election of Director: D. Mark Durcan |
Management |
For |
For |
| 1D. |
Election of Director: Richard W. Gochnauer |
Management |
For |
For |
| 1E. |
Election of Director: Lon R. Greenberg |
Management |
For |
For |
| 1F. |
Election of Director: Jane E. Henney, M.D. |
Management |
For |
For |
| 1G. |
Election of Director: Kathleen W. Hyle |
Management |
For |
For |
| 1H. |
Election of Director: Michael J. Long |
Management |
For |
For |
| 1I. |
Election of Director: Henry W. McGee |
Management |
For |
For |
| 1J. |
Election of Director: Dennis M. Nally |
Management |
For |
For |
| 2. |
Ratification of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal year 2020. |
Management |
For |
For |
| 3. |
Advisory vote to approve the compensation of named executive officers. |
Management |
For |
For |
| 4. |
Stockholder proposal, if properly presented, to permit stockholders to act by written consent. |
Shareholder |
Against |
For |
| 5. |
Stockholder proposal, if properly presented, regarding the use of a deferral period for certain compensation of senior executives. |
Shareholder |
Against |
For |
AMGEN INC.
| Security |
031162100 |
Meeting Type |
Annual |
| Ticker Symbol |
AMGN |
Meeting Date |
19-May-2020 |
| Record Date |
20-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Dr. Wanda M. Austin |
Management |
For |
For |
| 1B. |
Election of Director: Mr. Robert A. Bradway |
Management |
For |
For |
| 1C. |
Election of Director: Dr. Brian J. Druker |
Management |
For |
For |
| 1D. |
Election of Director: Mr. Robert A. Eckert |
Management |
For |
For |
| 1E. |
Election of Director: Mr. Greg C. Garland |
Management |
For |
For |
| 1F. |
Election of Director: Mr. Fred Hassan |
Management |
For |
For |
| 1G. |
Election of Director: Mr. Charles M. Holley, Jr. |
Management |
For |
For |
| 1H. |
Election of Director: Dr. Tyler Jacks |
Management |
For |
For |
| 1I. |
Election of Director: Ms. Ellen J. Kullman |
Management |
For |
For |
| 1J. |
Election of Director: Dr. Ronald D. Sugar |
Management |
For |
For |
| 1K. |
Election of Director: Dr. R. Sanders Williams |
Management |
For |
For |
| 2. |
Advisory vote to approve our executive compensation. |
Management |
For |
For |
| 3. |
To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 4. |
Stockholder proposal to require an independent board chair. |
Shareholder |
For |
Against |
Field: Page; Sequence: 8
Field: /Page
AMICUS THERAPEUTICS, INC.
| Security |
03152W109 |
Meeting Type |
Annual |
| Ticker Symbol |
FOLD |
Meeting Date |
04-Jun-2020 |
| Record Date |
13-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Lynn D. Bleil |
For |
For |
|
2 |
Bradley L. Campbell |
For |
For |
|
3 |
Robert Essner |
For |
For |
|
4 |
Ted W. Love, M.D. |
For |
For |
| 2. |
Approval of the Amended and Restated 2007 Equity Incentive Plan to add 9,500,000 shares to the equity pool. |
Management |
For |
For |
| 3. |
Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 4. |
Approval, on an advisory basis, the Company's executive compensation. |
Management |
For |
For |
AMPHIVENA THERAPEUTICS, INC.
| Security |
N/A |
Meeting Type |
Written Consent |
| Ticker Symbol |
N/A |
Meeting Date |
27-Aug-2019 |
| Record Date |
N/A |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
Approval of Certificate of Amendment to Amended and Restated Certificate of Incorporation |
Management |
For |
For |
| 2. |
Increase in Authorized Shares Reserved for Issuance under the Company's 2013 Stock Incentive Plan |
Management |
For |
For |
| 3. |
Omnibus Resolutions |
Management |
For |
For |
AMPHIVENA THERAPEUTICS, INC.
| Security |
N/A |
Meeting Type |
Written Consent |
| Ticker Symbol |
N/A |
Meeting Date |
4-Nov-2019 |
| Record Date |
N/A |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
Election of Director |
Management |
For |
For |
| 2. |
Increase in Authorized Shares Reserved for Issuance under the Company's 2013 Stock Incentive Plan |
Management |
For |
For |
| 3. |
Omnibus Resolutions |
Management |
For |
For |
ANAPTYSBIO INC
| Security |
032724106 |
Meeting Type |
Annual |
| Ticker Symbol |
ANAB |
Meeting Date |
19-Jun-2020 |
| Record Date |
20-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Hollings Renton |
For |
For |
|
2 |
John P. Schmid |
For |
For |
| 2. |
To ratify the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 3. |
Non-binding advisory vote on compensation of our named executive officers. |
Management |
For |
For |
ANTHEM, INC.
| Security |
036752103 |
Meeting Type |
Annual |
| Ticker Symbol |
ANTM |
Meeting Date |
21-May-2020 |
| Record Date |
16-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1.1 |
Election of Director: Gail K. Boudreaux |
Management |
For |
For |
| 1.2 |
Election of Director: R. Kerry Clark |
Management |
For |
For |
| 1.3 |
Election of Director: Robert L. Dixon, Jr. |
Management |
For |
For |
| 2. |
Advisory vote to approve the compensation of our named executive officers. |
Management |
For |
For |
| 3. |
To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2020. |
Management |
For |
For |
| 4. |
Shareholder proposal to allow shareholders owning 10% or more of our common stock to call a special meeting of shareholders. |
Shareholder |
Against |
For |
APELLIS PHARMACEUTICALS INC.
| Security |
03753U106 |
Meeting Type |
Annual |
| Ticker Symbol |
APLS |
Meeting Date |
01-Jun-2020 |
| Record Date |
13-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Gerald Chan |
For |
For |
|
2 |
Cedric Francois |
For |
For |
| 2. |
To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 3. |
To approve an advisory vote on executive compensation. |
Management |
For |
For |
Field: Page; Sequence: 9
Field: /Page
Field: Split-Segment; Name: 1
ARENA PHARMACEUTICALS, INC.
| Security |
040047607 |
Meeting Type |
Annual |
| Ticker Symbol |
ARNA |
Meeting Date |
12-Jun-2020 |
| Record Date |
20-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Jayson Dallas, M.D. |
For |
For |
|
2 |
Oliver Fetzer, Ph.D. |
For |
For |
|
3 |
Kieran T. Gallahue |
For |
For |
|
4 |
Jennifer Jarrett |
For |
For |
|
5 |
Amit D. Munshi |
For |
For |
|
6 |
Garry A. Neil, M.D. |
For |
For |
|
7 |
Tina S. Nova, Ph.D. |
For |
For |
|
8 |
Manmeet S. Soni |
For |
For |
| 2. |
To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice. |
Management |
For |
For |
| 3. |
To approve an amendment to our Amended and Restated Certificate of Incorporation to effect an increase in the total number of authorized shares of our common stock. |
Management |
For |
For |
| 4. |
To approve the Arena Pharmaceuticals, Inc. 2020 Long- Term Incentive Plan. |
Management |
For |
For |
| 5. |
To ratify the appointment of KPMG LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2020. |
Management |
For |
For |
ARGENX SE
| Security |
04016X101 |
Meeting Type |
Special |
| Ticker Symbol |
ARGX |
Meeting Date |
25-Nov-2019 |
| Record Date |
28-Oct-2019 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 2. |
Amendment of the articles of association of argenx SE to increase the maximum share capital and granting a proxy to each of the directors of the Company and employees of Freshfields Bruckhaus Deringer LLP in having the deed of amendment executed. |
Management |
For |
For |
| 3. |
Approval of the amended argenx option plan. |
Management |
For |
For |
| 4. |
Authorization of the board of directors to grant options(rights to subscribe for shares) up to a maximum of 4% of the outstanding capital at the date of the general meeting, pursuant to, and within the limits of, the argenx option plan, for a period of 18 months from the general meeting. |
Management |
For |
For |
ARGENX SE
| Security |
04016X101 |
Meeting Type |
Annual |
| Ticker Symbol |
ARGX |
Meeting Date |
12-May-2020 |
| Record Date |
14-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 3. |
Adoption of the new remuneration policy |
Management |
For |
For |
| 4. |
Advisory vote to approve the 2019 remuneration report |
Management |
For |
For |
| 5b. |
Adoption of the 2019 annual accounts |
Management |
For |
For |
| 5d. |
Allocation of losses of the Company in the financial year 2019 to the retained earnings of the Company |
Management |
For |
For |
| 5e. |
Proposal to release the members of the board of directors from liability for their respective duties carried out in the financial year 2019 |
Management |
For |
For |
| 6. |
Re-appointment of Pamela Klein as non-executive director to the board of directors of the Company |
Management |
For |
For |
| 7. |
Authorization of the board of directors to grant rights to subscribe for shares in the capital of the Company up to a maximum of 4% of the outstanding capital at the date of the general meeting, pursuant to, and within the limits of, the argenx option plan, for a period of 18 months from the annual general meeting and to limit or exclude statutory pre-emptive rights, if any |
Management |
For |
For |
| 8. |
Authorization of the board of directors to issue shares and grant rights to subscribe for shares in the share capital of the Company up to a maximum of 10% of the outstanding capital at the date of the general meeting, for a period of 18 months from the annual general meeting and to limit or exclude statutory pre-emptive rights, if any |
Management |
For |
For |
| 9. |
Authorization of the board of directors to issue additional shares in the share capital of the company up to a maximum of 10% of the outstanding share capital at the date of the general meeting (in addition to the authorizations under 7 and 8), for a period starting on the date of this general meeting and ending on 31 December 2020, for the purpose of a possible public offering of such shares and to limit or exclude statutory pre-emptive rights, if any |
Management |
For |
For |
| 10. |
Appointment of Deloitte Accountants B.V. as statutory auditor for the 2020 financial year |
Management |
For |
For |
Field: Page; Sequence: 10
Field: /Page
ARROWHEAD PHARMACEUTICALS, INC.
| Security |
04280A100 |
Meeting Type |
Annual |
| Ticker Symbol |
ARWR |
Meeting Date |
19-Mar-2020 |
| Record Date |
22-Jan-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Christopher Anzalone |
For |
For |
|
2 |
Marianne De Backer |
For |
For |
|
3 |
Mauro Ferrari |
For |
For |
|
4 |
Douglass Given |
For |
For |
|
5 |
Michael S. Perry |
For |
For |
|
6 |
William Waddill |
For |
For |
| 2. |
To approve, in an advisory (non-binding) vote, the compensation paid to the Company's named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the compensation tables and narrative discussion. |
Management |
For |
For |
| 3. |
To approve an amendment to the Company's Amended and Restated Bylaws to implement a majority vote standard in uncontested elections of directors. |
Management |
For |
For |
| 4. |
To ratify the selection of Rose, Snyder & Jacobs LLP as independent auditors of the Company for the fiscal year ending September 30, 2020. |
Management |
For |
For |
ASCENDIS PHARMA A S
| Security |
04351P101 |
Meeting Type |
Annual |
| Ticker Symbol |
ASND |
Meeting Date |
29-May-2020 |
| Record Date |
24-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
Election of Chairman of the Meeting |
Management |
For |
For |
| 2. |
Report on the Company's Activities during the Past Year |
Management |
For |
For |
| 3. |
Presentation of Audited Annual Report with Auditor's Statement for Approval and Discharge of the Board of Directors and Management |
Management |
For |
For |
| 4. |
Resolution on Application of Profits or Covering of Losses as per the Adopted Annual Report |
Management |
For |
For |
| 5A. |
Election of Board Member Class II, with a term expiring at the annual general meeting to be held in 2022: Albert Cha |
Management |
For |
For |
| 5B. |
Election of Board Member Class II, with a term expiring at the annual general meeting to be held in 2022: Birgitte Volck |
Management |
For |
For |
| 5C. |
Election of Board Member Class II, with a term expiring at the annual general meeting to be held in 2022: Lars Holtug |
Management |
For |
For |
| 6. |
Election of State-authorized Public Auditor |
Management |
For |
For |
| 7. |
Any proposals from the Board of Directors and/or Shareholders The Board of Directors proposes to amend the Articles of Association by renewing the authorisation to the Board of Directors to issue up to nominal 2,000,000 new warrants. The exercise price of such warrants shall be determined by the Board of Directors and shall equal at least to the market price of the shares at the time of issuance. Please refer to the Notice for additional information. |
Management |
For |
For |
Field: Page; Sequence: 11
Field: /Page
ATRECA INC
| Security |
04965G109 |
Meeting Type |
Annual |
| Ticker Symbol |
BCEL |
Meeting Date |
10-Jun-2020 |
| Record Date |
17-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
David Lacey, MD |
For |
For |
|
2 |
Lindsey Rolfe, MBChB |
For |
For |
| 2. |
Ratification of the selection of OUM & Co. LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020. |
Management |
For |
For |
AURINIA PHARMACEUTICALS INC.
| Security |
05156V102 |
Meeting Type |
Annual and Special Meeting |
| Ticker Symbol |
AUPH |
Meeting Date |
02-Jun-2020 |
| Record Date |
20-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 01 |
TO FIX THE NUMBER OF DIRECTORS TO BE ELECTED AT NINE (9). |
Management |
For |
For |
| 02 |
DIRECTOR |
Management |
|
|
|
1 |
DR. GEORGE MILNE |
For |
For |
|
2 |
MR. PETER GREENLEAF |
For |
For |
|
3 |
DR. DAVID R.W. JAYNE |
For |
For |
|
4 |
MR. JOSEPH P. HAGAN |
For |
For |
|
5 |
DR. MICHAEL HAYDEN |
For |
For |
|
6 |
DR. DANIEL BILLEN |
For |
For |
|
7 |
MR. R.H. MACKAY-DUNN |
For |
For |
|
8 |
MS. JILL LEVERSAGE |
For |
For |
|
9 |
MR. TIMOTHY P. WALBERT |
For |
For |
| 03 |
REAPPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS AUDITORS OF THE COMPANY FOR THE ENSUING YEAR. |
Management |
For |
For |
| 04 |
TO CONSIDER AND, IF DEEMED APPROPRIATE, TO PASS A NON-BINDING ADVISORY "SAY ON PAY" RESOLUTION APPROVING THE COMPANY'S APPROACH TO EXECUTIVE COMPENSATION, THE FULL TEXT OF WHICH IS SET OUT IN THE COMPANY'S CIRCULAR FOR THE MEETING. |
Management |
For |
For |
| 05 |
TO CONSIDER, AND IF DEEMED APPROPRIATE, APPROVE, WITH OR WITHOUT VARIATION, AN ORDINARY RESOLUTION RATIFYING, CONFIRMING AND APPROVING THE COMPANY'S AMENDED AND RESTATED BY-LAW NO. 2 AS ADOPTED BY THE COMPANY'S BOARD OF DIRECTORS (THE "BOARD") TO ALLOW THE COMPANY TO HOLD FULLY VIRTUAL SHAREHOLDER MEETINGS AND SHAREHOLDER MEETINGS OUTSIDE OF ALBERTA, AMONG OTHER AMENDMENTS, THE FULL TEXT OF WHICH IS SET OUT IN THE COMPANY'S CIRCULAR FOR THE MEETING. |
Management |
For |
For |
| 06 |
TO CONSIDER, AND IF DEEMED APPROPRIATE, APPROVE, WITH OR WITHOUT VARIATION, A SPECIAL RESOLUTION AMENDING THE ARTICLES OF THE COMPANY TO PERMIT MEETINGS OF SHAREHOLDERS TO BE HELD OUTSIDE OF ALBERTA, THE FULL TEXT OF WHICH IS SET OUT IN THE COMPANY'S CIRCULAR FOR THE MEETING. |
Management |
For |
For |
| 07 |
TO |
|
|
|
| CONSIDER AND, IF DEEMED APPROPRIATE, APPROVE, WITH OR WITHOUT VARIATION, AN ORDINARY RESOLUTION RATIFYING, CONFIRMING AND |
|
|
|
|
| APPROVING THE COMPANY'S AMENDMENTS TO THE STOCK OPTION PLAN AS ADOPTED BY THE BOARD TO EXPAND THE TYPES OF EQUITY BASED AWARDS |
|
|
|
|
| AVAILABLE TO GRANT, THE FULL TEXT OF WHICH IS SET OUT IN THE COMPANY'S CIRCULAR FOR THE MEETING. |
Management |
For |
For |
|
| 08 |
TO CONSIDER AND, IF DEEMED APPROPRIATE, APPROVE, WITH OR WITHOUT VARIATION, AN ORDINARY RESOLUTION APPROVING ALL UNALLOCATED ENTITLEMENTS UNDER THE COMPANY'S STOCK OPTION PLAN, THE FULL TEXT OF WHICH IS SET OUT IN THE COMPANY'S CIRCULAR FOR THE MEETING. |
Management |
For |
For |
Field: Page; Sequence: 12
Field: /Page
AVROBIO, INC.
| Security |
05455M100 |
Meeting Type |
Annual |
| Ticker Symbol |
AVRO |
Meeting Date |
04-Jun-2020 |
| Record Date |
06-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Ian Clark |
For |
For |
|
2 |
Annalisa Jenkins |
For |
For |
| 2. |
To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 3. |
To approve an amendment to the AVROBIO, Inc. 2018 Stock Option and Incentive Plan. |
Management |
For |
For |
AXONICS MODULATION TECHNOLOGIES INC
| Security |
05465P101 |
Meeting Type |
Annual |
| Ticker Symbol |
AXNX |
Meeting Date |
24-Jun-2020 |
| Record Date |
28-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Raymond W. Cohen |
Management |
For |
For |
| 1B. |
Election of Director: Erik Amble, Ph.D. |
Management |
For |
For |
| 1C. |
Election of Director: Juliet Tammenoms Bakker |
Management |
For |
For |
| 1D. |
Election of Director: Robert E. McNamara |
Management |
For |
For |
| 1E. |
Election of Director: Michael H. Carrel |
Management |
For |
For |
| 1F. |
Election of Director: Nancy Snyderman, M.D., |
Management |
For |
For |
| 1G. |
Election of Director: Jane E. Kiernan |
Management |
For |
For |
| 2. |
To ratify the selection of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
AXSOME THERAPEUTICS INC
| Security |
05464T104 |
Meeting Type |
Annual |
| Ticker Symbol |
AXSM |
Meeting Date |
05-Jun-2020 |
| Record Date |
09-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Mark Saad |
For |
For |
| 2. |
Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm of the fiscal year ending in December 31, 2020. |
Management |
For |
For |
Field: Page; Sequence: 13
Field: /Page
BAXTER INTERNATIONAL INC.
| Security |
071813109 |
Meeting Type |
Annual |
| Ticker Symbol |
BAX |
Meeting Date |
05-May-2020 |
| Record Date |
12-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: José (Joe) E. Almeida |
Management |
For |
For |
| 1B. |
Election of Director: Thomas F. Chen |
Management |
For |
For |
| 1C. |
Election of Director: John D. Forsyth |
Management |
For |
For |
| 1D. |
Election of Director: James R. Gavin III |
Management |
For |
For |
| 1E. |
Election of Director: Peter S. Hellman |
Management |
For |
For |
| 1F. |
Election of Director: Michael F. Mahoney |
Management |
For |
For |
| 1G. |
Election of Director: Patricia B. Morrison |
Management |
For |
For |
| 1H. |
Election of Director: Stephen N. Oesterle |
Management |
For |
For |
| 1I. |
Election of Director: Cathy R. Smith |
Management |
For |
For |
| 1J. |
Election of Director: Thomas T. Stallkamp |
Management |
For |
For |
| 1K. |
Election of Director: Albert P.L. Stroucken |
Management |
For |
For |
| 1L. |
Election of Director: Amy A. Wendell |
Management |
For |
For |
| 2. |
Advisory Vote to Approve Named Executive Officer |
|
|
|
|
Compensation |
Management |
For |
For |
| 3. |
Ratification of Appointment of Independent Registered Public Accounting Firm |
Management |
For |
For |
| 4. |
Stockholder Proposal - Independent Board Chairman |
Shareholder |
For |
Against |
| 5. |
Stockholder Proposal - Right to Act by Written Consent |
Shareholder |
For |
Against |
BECTON, DICKINSON AND COMPANY
| Security |
075887109 |
Meeting Type |
Annual |
| Ticker Symbol |
BDX |
Meeting Date |
28-Jan-2020 |
| Record Date |
09-Dec-2019 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Catherine M. Burzik |
Management |
For |
For |
| 1B. |
Election of Director: R. Andrew Eckert |
Management |
For |
For |
| 1C. |
Election of Director: Vincent A. Forlenza |
Management |
For |
For |
| 1D. |
Election of Director: Claire M. Fraser |
Management |
For |
For |
| 1E. |
Election of Director: Jeffrey W. Henderson |
Management |
For |
For |
| 1F. |
Election of Director: Christopher Jones |
Management |
For |
For |
| 1G. |
Election of Director: Marshall O. Larsen |
Management |
For |
For |
| 1H. |
Election of Director: David F. Melcher |
Management |
For |
For |
| 1I. |
Election of Director: Thomas E. Polen |
Management |
For |
For |
| 1J. |
Election of Director: Claire Pomeroy |
Management |
For |
For |
| 1K. |
Election of Director: Rebecca W. Rimel |
Management |
For |
For |
| 1L. |
Election of Director: Timothy M. Ring |
Management |
For |
For |
| 1M. |
Election of Director: Bertram L. Scott |
Management |
For |
For |
| 2. |
Ratification of selection of independent registered public accounting firm. |
Management |
For |
For |
| 3. |
Advisory vote to approve named executive officer compensation. |
Management |
For |
For |
| 4. |
Approval of amendment to BD's 2004 Employee and Director Equity-Based Compensation Plan. |
Management |
For |
For |
| 5. |
Approval of French Addendum to BD'S 2004 Employee and Director Equity-Based Compensation Plan. |
Management |
For |
For |
| 6. |
Shareholder proposal regarding special shareholder meetings. |
Shareholder |
Against |
For |
BEIGENE LTD
| Security |
07725L102 |
Meeting Type |
Special |
| Ticker Symbol |
BGNE |
Meeting Date |
27-Dec-2019 |
| Record Date |
27-Nov-2019 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1 |
THAT the issuance of approximately 20.5% of the Company's outstanding shares upon closing to Amgen Inc. ("Amgen") be and is hereby approved, pursuant to the terms of the Share Purchase Agreement (the "Share Purchase Agreement") by and between the Company and Amgen. |
Management |
For |
For |
| 2 |
THAT the Collaboration Agreement (the "Collaboration Agreement") dated October 31, 2019 by and between the Company, BeiGene Switzerland GmbH and Amgen and the transactions contemplated thereunder be and are hereby approved. |
Management |
For |
For |
| 3 |
THAT the annual caps in relation to the Collaboration Agreement be and are hereby approved. |
Management |
For |
For |
| 4 |
THAT Anthony C. Hooper be and is hereby elected to serve as a Class III director of the Company until the 2022 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal, subject to and effective upon the closing of the transactions contemplated by the Share Purchase Agreement and the Collaboration Agreement. |
Management |
For |
For |
Field: Page; Sequence: 14
Field: /Page
BEIGENE LTD
| Security |
07725L102 |
Meeting Type |
Annual |
| Ticker Symbol |
BGNE |
Meeting Date |
17-Jun-2020 |
| Record Date |
16-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1 |
Ordinary Resolution: THAT John V. Oyler be and is hereby re-elected to serve as a Class I director of the Company until the 2023 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal. |
Management |
For |
For |
| 2 |
Ordinary Resolution: THAT Timothy Chen be and is hereby re-elected to serve as a Class I director of the Company until the 2023 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal. |
Management |
For |
For |
| 3 |
Ordinary Resolution: THAT Jing-Shyh (Sam) Su be and is hereby re-elected to serve as a Class I director of the Company until the 2023 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal. |
Management |
For |
For |
| 4 |
Ordinary Resolution: THAT the appointment of Ernst & Young Hua Ming LLP and Ernst & Young as the Company's independent registered public accounting firms for the fiscal year ending December 31, 2020 be and is hereby approved, ratified and confirmed. |
Management |
For |
For |
| 5 |
Ordinary Resolution: THAT the granting of a share issue mandate to the Board of Directors to issue, allot or deal with unissued ordinary shares and/or American Depositary Shares not exceeding 20% of the total number of issued ordinary shares of the Company as at the date of passing of this ordinary resolution up to the next annual general meeting of the Company be and is hereby approved. |
Management |
For |
For |
| 6 |
Ordinary Resolution: THAT the Company and its underwriters be and are hereby authorized, in their sole discretion, to allocate to each of Baker Bros. Advisors LP and Hillhouse Capital Management, Ltd. and parties affiliated with each of them (the "Existing Shareholders"), up to a maximum amount of shares in order to maintain the same shareholding percentage of each of the Existing Shareholders (based on the then- outstanding share capital of the Company) before and after the ... (due to space limits, see proxy material for full proposal). |
Management |
For |
For |
| 7 |
Ordinary Resolution: THAT the Company and its underwriters be and are hereby authorized, in their sole discretion, to allocate to Amgen Inc. ("Amgen"), up to a maximum amount of shares in order to maintain the same shareholding percentage of Amgen (based on the then-outstanding share capital of the Company) before and after the allocation of the corresponding securities issued pursuant to an offering conducted pursuant to the general mandate set forth in Resolution 5 for a period of ... (due to space limits, see proxy material for full proposal). |
Management |
For |
For |
| 8 |
Ordinary Resolution: THAT the Amendment No. 1 to the Second Amended and Restated 2016 Share Option and Incentive Plan to increase the number of authorized shares available for issuance by 57,200,000 ordinary shares and to extend the term of the plan through April 13, 2030, as disclosed in the Proxy Statement, be and is hereby approved. |
Management |
For |
For |
| 9 |
Ordinary Resolution: THAT, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, be and is hereby approved. |
Management |
For |
For |
Field: Page; Sequence: 15
Field: /Page
BIO-TECHNE CORP
| Security |
09073M104 |
Meeting Type |
Annual |
| Ticker Symbol |
TECH |
Meeting Date |
24-Oct-2019 |
| Record Date |
30-Aug-2019 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
To set the number of Directors at nine. |
Management |
For |
For |
| 2A. |
Election of Director: Robert V. Baumgartner |
Management |
For |
For |
| 2B. |
Election of Director: John L. Higgins |
Management |
For |
For |
| 2C. |
Election of Director: Joseph D. Keegan |
Management |
For |
For |
| 2D. |
Election of Director: Charles R. Kummeth |
Management |
For |
For |
| 2E. |
Election of Director: Roeland Nusse |
Management |
For |
For |
| 2F. |
Election of Director: Alpna Seth |
Management |
For |
For |
| 2G. |
Election of Director: Randolph Steer |
Management |
For |
For |
| 2H. |
Election of Director: Rupert Vessey |
Management |
For |
For |
| 2I. |
Election of Director: Harold J. Wiens |
Management |
For |
For |
| 3. |
Cast a non-binding vote on named executive officer compensation. |
Management |
For |
For |
| 4. |
Ratify the appointment of the Company's independent registered public accounting firm for the 2020 fiscal year. |
Management |
For |
For |
BIOGEN INC.
| Security |
09062X103 |
Meeting Type |
Annual |
| Ticker Symbol |
BIIB |
Meeting Date |
03-Jun-2020 |
| Record Date |
06-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director for a one year term extending until the 2021 annual meeting: Alexander J. Denner |
Management |
For |
For |
| 1B. |
Election of Director for a one year term extending until the 2021 annual meeting: Caroline D. Dorsa |
Management |
For |
For |
| 1C. |
Election of Director for a one year term extending until the 2021 annual meeting: William A. Hawkins |
Management |
For |
For |
| 1D. |
Election of Director for a one year term extending until the 2021 annual meeting: Nancy L. Leaming |
Management |
For |
For |
| 1E. |
Election of Director for a one year term extending until the 2021 annual meeting: Jesus B. Mantas |
Management |
For |
For |
| 1F. |
Election of Director for a one year term extending until the 2021 annual meeting: Richard C. Mulligan |
Management |
For |
For |
| 1G. |
Election of Director for a one year term extending until the 2021 annual meeting: Robert W. Pangia |
Management |
For |
For |
| 1H. |
Election of Director for a one year term extending until the 2021 annual meeting: Stelios Papadopoulos |
Management |
For |
For |
| 1I. |
Election of Director for a one year term extending until the 2021 annual meeting: Brian S. Posner |
Management |
For |
For |
| 1J. |
Election of Director for a one year term extending until the 2021 annual meeting: Eric K. Rowinsky |
Management |
For |
For |
| 1K. |
Election of Director for a one year term extending until the 2021 annual meeting: Stephen A. Sherwin |
Management |
For |
For |
| 1L. |
Election of Director for a one year term extending until the 2021 annual meeting: Michel Vounatsos |
Management |
For |
For |
| 2. |
To ratify the selection of PricewaterhouseCoopers LLP as Biogen Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 3. |
Say on Pay - To approve an advisory vote on executive compensation. |
Management |
For |
For |
Field: Page; Sequence: 16
Field: /Page
BIOHAVEN PHARMACEUTICAL HLDG CO LTD
| Security |
G11196105 |
Meeting Type |
Annual |
| Ticker Symbol |
BHVN |
Meeting Date |
30-Apr-2020 |
| Record Date |
17-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director for a term expiring at the 2023 Annual Meeting of Shareholders: Dr. Declan Doogan |
Management |
For |
For |
| 1B. |
Election of Director for a term expiring at the 2023 Annual Meeting of Shareholders: Dr. Vlad Coric |
Management |
For |
For |
| 2. |
Ratification of appointment of Ernst & Young LLP as independent auditors for fiscal year 2020. |
Management |
For |
For |
| 3. |
To approve, on a non-binding advisory basis, the compensation of the Named Executive Officers. |
Management |
For |
For |
BIOMARIN PHARMACEUTICAL INC.
| Security |
09061G101 |
Meeting Type |
Annual |
| Ticker Symbol |
BMRN |
Meeting Date |
27-May-2020 |
| Record Date |
30-Mar-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Jean-Jacques Bienaimé |
For |
For |
|
2 |
Elizabeth M. Anderson |
For |
For |
|
3 |
Willard Dere |
For |
For |
|
4 |
Michael Grey |
For |
For |
|
5 |
Elaine J. Heron |
For |
For |
|
6 |
Robert J. Hombach |
For |
For |
|
7 |
V. Bryan Lawlis |
For |
For |
|
8 |
Richard A. Meier |
For |
For |
|
9 |
David E.I. Pyott |
For |
For |
|
10 |
Dennis J. Slamon |
For |
For |
| 2. |
To ratify the selection of KPMG LLP as the independent registered public accounting firm for BioMarin for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 3. |
To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement. |
Management |
For |
For |
BLUEBIRD BIO, INC.
| Security |
09609G100 |
Meeting Type |
Annual |
| Ticker Symbol |
BLUE |
Meeting Date |
18-Jun-2020 |
| Record Date |
23-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Class I Director: Nick Leschly |
Management |
For |
For |
| 1B. |
Election of Class I Director: Douglas A. Melton, Ph.D. |
Management |
For |
For |
| 1C. |
Election of Class I Director: Mark Vachon |
Management |
For |
For |
| 2. |
To hold a non-binding advisory vote on the compensation paid to the Company's named executive officers. |
Management |
For |
For |
| 3. |
To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
BLUEPRINT MEDICINES CORPORATION
| Security |
09627Y109 |
Meeting Type |
Annual |
| Ticker Symbol |
BPMC |
Meeting Date |
23-Jun-2020 |
| Record Date |
24-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Alexis Borisy |
For |
For |
|
2 |
Charles A. Rowland, Jr. |
For |
For |
|
3 |
Lonnel Coats |
For |
For |
| 2. |
To approve an advisory vote on named executive officer compensation. |
Management |
For |
For |
| 3. |
Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
Field: Page; Sequence: 17
Field: /Page
BOSTON SCIENTIFIC CORPORATION
| Security |
101137107 |
Meeting Type |
Annual |
| Ticker Symbol |
BSX |
Meeting Date |
07-May-2020 |
| Record Date |
13-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Nelda J. Connors |
Management |
For |
For |
| 1B. |
Election of Director: Charles J. Dockendorff |
Management |
For |
For |
| 1C. |
Election of Director: Yoshiaki Fujimori |
Management |
For |
For |
| 1D. |
Election of Director: Donna A. James |
Management |
For |
For |
| 1E. |
Election of Director: Edward J. Ludwig |
Management |
For |
For |
| 1F. |
Election of Director: Stephen P. MacMillan |
Management |
For |
For |
| 1G. |
Election of Director: Michael F. Mahoney |
Management |
For |
For |
| 1H. |
Election of Director: David J. Roux |
Management |
For |
For |
| 1I. |
Election of Director: John E. Sununu |
Management |
For |
For |
| 1J. |
Election of Director: Ellen M. Zane |
Management |
For |
For |
| 2. |
To approve, on a non-binding, advisory basis, named executive officer compensation. |
Management |
For |
For |
| 3. |
To approve an amendment and restatement of the Company's 2011 Long-Term Incentive Plan. |
Management |
For |
For |
| 4. |
To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the 2020 fiscal year. |
Management |
For |
For |
| 5. |
To consider and vote upon a stockholder proposal requesting a report on inclusion of non-management employee representation on the Board of Directors. |
Shareholder |
Against |
For |
BRIDGEBIO PHARMA INC
| Security |
10806X102 |
Meeting Type |
Annual |
| Ticker Symbol |
BBIO |
Meeting Date |
02-Jun-2020 |
| Record Date |
15-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
James C. Momtazee |
For |
For |
|
2 |
Richard H. Scheller PhD |
For |
For |
| 2. |
To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020. |
Management |
For |
For |
| 3. |
To approve the Company's Amended and Restated 2019 Stock Option and Incentive Plan to, among other things, increase the number of shares of common stock reserved for issuance thereunder by 2,500,000 shares. |
Management |
For |
For |
BRISTOL-MYERS SQUIBB COMPANY
| Security |
110122108 |
Meeting Type |
Annual |
| Ticker Symbol |
BMY |
Meeting Date |
05-May-2020 |
| Record Date |
16-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Peter J. Arduini |
Management |
For |
For |
| 1B. |
Election of Director: Robert Bertolini |
Management |
For |
For |
| 1C. |
Election of Director: Michael W. Bonney |
Management |
For |
For |
| 1D. |
Election of Director: Giovanni Caforio, M.D. |
Management |
For |
For |
| 1E. |
Election of Director: Matthew W. Emmens |
Management |
For |
For |
| 1F. |
Election of Director: Julia A. Haller, M.D. |
Management |
For |
For |
| 1G. |
Election of Director: Dinesh C. Paliwal |
Management |
For |
For |
| 1H. |
Election of Director: Theodore R. Samuels |
Management |
For |
For |
| 1I. |
Election of Director: Vicki L. Sato, Ph.D. |
Management |
For |
For |
| 1J. |
Election of Director: Gerald L. Storch |
Management |
For |
For |
| 1K. |
Election of Director: Karen H. Vousden, Ph.D. |
Management |
For |
For |
| 1L. |
Election of Director: Phyllis R. Yale |
Management |
For |
For |
| 2. |
Advisory vote to approve the compensation of our Named Executive Officers. |
Management |
For |
For |
| 3. |
Ratification of the |
|
|
|
| appointment of an independent registered public accounting |
|
|
|
|
| firm. |
Management |
For |
For |
|
| 4. |
Shareholder Proposal on Separate Chair & CEO. |
Shareholder |
For |
Against |
| 5. |
Shareholder Proposal on Shareholder Right to Act by Written Consent. |
Shareholder |
Against |
For |
Field: Page; Sequence: 18
Field: /Page
CENTENE CORPORATION
| Security |
15135B101 |
Meeting Type |
Annual |
| Ticker Symbol |
CNC |
Meeting Date |
28-Apr-2020 |
| Record Date |
28-Feb-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
ELECTION OF DIRECTOR: Michael F. Neidorff |
Management |
For |
For |
| 1B. |
ELECTION OF DIRECTOR: H. James Dallas |
Management |
For |
For |
| 1C. |
ELECTION OF DIRECTOR: Robert K. Ditmore |
Management |
For |
For |
| 1D. |
ELECTION OF DIRECTOR: Richard A. Gephardt |
Management |
For |
For |
| 1E. |
ELECTION OF DIRECTOR: Lori J. Robinson |
Management |
For |
For |
| 1F. |
ELECTION OF DIRECTOR: William L. Trubeck |
Management |
For |
For |
| 2. |
ADVISORY RESOLUTION TO APPROVE EXECUTIVE COMPENSATION. |
Management |
For |
For |
| 3. |
RATIFICATION OF APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2020. |
Management |
For |
For |
| 4. |
APPROVAL OF AMENDMENT TO THE 2002 EMPLOYEE STOCK PURCHASE PLAN, AS AMENDED AND RESTATED. |
Management |
For |
For |
| 5. |
THE STOCKHOLDER PROPOSAL ON POLITICAL SPENDING DISCLOSURES AS DESCRIBED IN THE PROXY STATEMENT. |
Shareholder |
Against |
For |
| 6. |
THE STOCKHOLDER PROPOSAL ON THE ELIMINATION OF SUPERMAJORITY VOTING PROVISIONS AS DESCRIBED IN THE PROXY STATEMENT. |
Shareholder |
Against |
For |
CHARLES RIVER LABORATORIES INTL., INC.
| Security |
159864107 |
Meeting Type |
Annual |
| Ticker Symbol |
CRL |
Meeting Date |
06-May-2020 |
| Record Date |
16-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: James C. Foster |
Management |
For |
For |
| 1B. |
Election of Director: Nancy C. Andrews |
Management |
For |
For |
| 1C. |
Election of Director: Robert J. Bertolini |
Management |
For |
For |
| 1D. |
Election of Director: Stephen D. Chubb |
Management |
For |
For |
| 1E. |
Election of Director: Deborah T. Kochevar |
Management |
For |
For |
| 1F. |
Election of Director: Martin W. MacKay |
Management |
For |
For |
| 1G. |
Election of Director: George E. Massaro |
Management |
For |
For |
| 1H. |
Election of Director: George M. Milne, Jr. |
Management |
For |
For |
| 1I. |
Election of Director: C. Richard Reese |
Management |
For |
For |
| 1J. |
Election of Director: Richard F. Wallman |
Management |
For |
For |
| 1K. |
Election of Director: Virginia M. Wilson |
Management |
For |
For |
| 2. |
Say on Pay - An advisory vote to approve our executive compensation. |
Management |
For |
For |
| 3. |
Proposal to Amend the 2018 Incentive Plan. |
Management |
For |
For |
| 4. |
Proposal to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accountants for the fiscal year ending December 26, 2020 |
Management |
For |
For |
CIGNA CORPORATION
| Security |
125523100 |
Meeting Type |
Annual |
| Ticker Symbol |
CI |
Meeting Date |
22-Apr-2020 |
| Record Date |
24-Feb-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: David M. Cordani |
Management |
For |
For |
| 1B. |
Election of Director: William J. DeLaney |
Management |
For |
For |
| 1C. |
Election of Director: Eric J. Foss |
Management |
For |
For |
| 1D. |
Election of Director: Elder Granger, MD, MG, USA |
Management |
For |
For |
| 1E. |
Election of Director: Isaiah Harris, Jr. |
Management |
For |
For |
| 1F. |
Election of Director: Roman Martinez IV |
Management |
For |
For |
| 1G. |
Election of Director: Kathleen M. Mazzarella |
Management |
For |
For |
| 1H. |
Election of Director: Mark B. McClellan, MD, PhD |
Management |
For |
For |
| 1I. |
Election of Director: John M. Partridge |
Management |
For |
For |
| 1J. |
Election of Director: William L. Roper, MD, MPH |
Management |
For |
For |
| 1K. |
Election of Director: Eric C. Wiseman |
Management |
For |
For |
| 1L. |
Election of Director: Donna F. Zarcone |
Management |
For |
For |
| 2. |
Advisory approval of Cigna's executive compensation. |
Management |
For |
For |
| 3. |
Ratification of appointment of PricewaterhouseCoopers LLP as Cigna's independent registered public accounting firm for 2020. |
Management |
For |
For |
| 4. |
Shareholder proposal - Shareholder right to call a special meeting. |
Shareholder |
Against |
For |
| 5. |
Shareholder proposal - Gender pay gap report. |
Shareholder |
Against |
For |
Field: Page; Sequence: 19
Field: /Page
Field: Split-Segment; Name: 2
COHERUS BIOSCIENCES INC
| Security |
19249H103 |
Meeting Type |
Annual |
| Ticker Symbol |
CHRS |
Meeting Date |
22-May-2020 |
| Record Date |
31-Mar-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Dennis M. Lanfear |
For |
For |
|
2 |
Mats Wahlström |
For |
For |
|
3 |
James I. Healy, MD, PhD |
For |
For |
| 2. |
To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 3. |
A non-binding, advisory resolution to approve the compensation of our named executive officers (a "Say- on-Pay" vote). |
Management |
For |
For |
CRISPR THERAPEUTICS AG
| Security |
H17182108 |
Meeting Type |
Annual |
| Ticker Symbol |
CRSP |
Meeting Date |
11-Jun-2020 |
| Record Date |
13-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
The approval of the annual report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2019. |
Management |
For |
For |
| 2. |
The approval of the appropriation of financial results. |
Management |
For |
For |
| 3. |
The discharge of the members of the Board of Directors and Executive Committee. |
Management |
For |
For |
| 4A. |
Re-election of Rodger Novak, M.D., as member and Chairman |
Management |
For |
For |
| 4B. |
Re-election of Samarth Kulkarni, Ph.D. |
Management |
For |
For |
| 4C. |
Re-election of Ali Behbahani, M.D. |
Management |
For |
For |
| 4D. |
Re-election of Bradley Bolzon, Ph.D. |
Management |
For |
For |
| 4E. |
Re-election of Simeon J. George, M.D. |
Management |
For |
For |
| 4F. |
Re-election of John T. Greene |
Management |
For |
For |
| 4G. |
Re-election of Katherine A. High, M.D. |
Management |
For |
For |
| 4H. |
Election of Douglas A. Treco, Ph.D. |
Management |
For |
For |
| 5A. |
Election of the member of the Compensation Committee: Ali Behbahani, M.D. |
Management |
For |
For |
| 5B. |
Re-election of the member of the Compensation Committee: Simeon J. George, M.D. |
Management |
For |
For |
| 5C. |
Re-election of the member of the Compensation Committee: John T. Greene |
Management |
For |
For |
| 6A. |
Binding vote on total non-performance-related compensation for members of the Board of Directors from the 2020 Annual General Meeting to the 2021 Annual General Meeting of Shareholders. |
Management |
For |
For |
| 6B. |
Binding vote on equity for members of the Board of Directors from the 2020 Annual General Meeting to the 2021 Annual General Meeting of Shareholders. |
Management |
For |
For |
| 6C. |
Binding vote on total non-performance-related compensation for members of the Executive Committee from July 1, 2020 to June 30, 2021. |
Management |
For |
For |
| 6D. |
Binding vote on total variable compensation for members of the Executive Committee for the current year ending December 31, 2020. |
Management |
For |
For |
| 6E. |
Binding vote on equity for members of the Executive Committee from the 2020 Annual General Meeting to the 2021 Annual General Meeting of Shareholders. |
Management |
For |
For |
| 7. |
The approval of an increase in the Conditional Share Capital for Employee Benefit Plans. |
Management |
For |
For |
| 8. |
The approval of an Amendment to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan. |
Management |
Against |
Against |
| 9. |
The approval of increasing the maximum number of authorized share capital and extending the date by which the Board of Directors may increase share capital. |
Management |
For |
For |
| 10. |
The re-election of the independent voting rights representative. |
Management |
For |
For |
| 11. |
The re-election of the auditors. |
Management |
For |
For |
| 12. |
The transaction of any other business that may properly come before the 2020 Annual General Meeting or any adjournment or postponement thereof. |
Management |
For |
For |
Field: Page; Sequence: 20
Field: /Page
CURASEN THERAPEUTICS, INC.
| Security |
N/A |
Meeting Type |
Written Consent |
| Ticker Symbol |
N/A |
Meeting Date |
6-Jan-20 |
| Record Date |
N/A |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1 |
Amendment to CuraSen Therapeutics, Inc. A&R 2016 Equity Incentive Plan |
Management |
For |
For |
| 2 |
General Authority and ratification |
Management |
For |
For |
CVS HEALTH CORPORATION
| Security |
126650100 |
Meeting Type |
Annual |
| Ticker Symbol |
CVS |
Meeting Date |
14-May-2020 |
| Record Date |
18-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Fernando Aguirre |
Management |
For |
For |
| 1B. |
Election of Director: C. David Brown II |
Management |
For |
For |
| 1C. |
Election of Director: Alecia A. DeCoudreaux |
Management |
For |
For |
| 1D. |
Election of Director: Nancy-Ann M. DeParle |
Management |
For |
For |
| 1E. |
Election of Director: David W. Dorman |
Management |
For |
For |
| 1F. |
Election of Director: Roger N. Farah |
Management |
For |
For |
| 1G. |
Election of Director: Anne M. Finucane |
Management |
For |
For |
| 1H. |
Election of Director: Edward J. Ludwig |
Management |
For |
For |
| 1I. |
Election of Director: Larry J. Merlo |
Management |
For |
For |
| 1J. |
Election of Director: Jean-Pierre Millon |
Management |
For |
For |
| 1K. |
Election of Director: Mary L. Schapiro |
Management |
For |
For |
| 1L. |
Election of Director: William C. Weldon |
Management |
For |
For |
| 1M. |
Election of Director: Tony L. White |
Management |
For |
For |
| 2. |
Ratification of the appointment of our independent registered public accounting firm for 2020. |
Management |
For |
For |
| 3. |
Say on Pay, a proposal to approve, on an advisory basis, the Company's executive compensation. |
Management |
For |
For |
| 4. |
Proposal to amend the Company's 2017 Incentive Compensation Plan to increase the number of shares authorized to be issued under the Plan. |
Management |
For |
For |
| 5. |
Proposal to amend the Company's 2007 Employee Stock Purchase Plan to increase the number of shares available for sale under the Plan. |
Management |
For |
For |
| 6. |
Stockholder proposal for reducing the ownership threshold to request a stockholder action by written consent. |
Shareholder |
Against |
For |
| 7. |
Stockholder proposal regarding our independent Board Chair. |
Shareholder |
Against |
For |
CYMABAY THERAPEUTICS INC
| Security |
23257D103 |
Meeting Type |
Annual |
| Ticker Symbol |
CBAY |
Meeting Date |
23-Jun-2020 |
| Record Date |
28-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Sujal Shah |
For |
For |
|
2 |
Caroline Loewy |
For |
For |
|
3 |
Paul F. Truex |
For |
For |
|
4 |
Kurt von Emster |
For |
For |
|
5 |
Robert J. Wills, Ph.D. |
For |
For |
| 2. |
Ratification of selection, by the Audit Committee of the Board, of Ernst & Young LLP as the independent registered public accounting firm of CymaBay for its fiscal year ending December 31, 2020. |
Management |
For |
For |
| 3. |
Advisory vote to approve the compensation of our named executive officers as disclosed in the proxy statement. |
Management |
For |
For |
| 4. |
To vote on an amendment to the CymaBay Amended and Restated Certificate of Incorporation to increase the number of authorized shares of our common stock from 100,000,000 shares to 200,000,000 shares. |
Management |
For |
For |
Field: Page; Sequence: 21
Field: /Page
DANAHER CORPORATION
| Security |
235851102 |
Meeting Type |
Annual |
| Ticker Symbol |
DHR |
Meeting Date |
05-May-2020 |
| Record Date |
09-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Linda Hefner Filler |
Management |
For |
For |
| 1B. |
Election of Director: Thomas P. Joyce, Jr. |
Management |
For |
For |
| 1C. |
Election of Director: Teri List-Stoll |
Management |
For |
For |
| 1D. |
Election of Director: Walter G. Lohr, Jr. |
Management |
For |
For |
| 1E. |
Election of Director: Jessica L. Mega, MD, MPH |
Management |
For |
For |
| 1F. |
Election of Director: Pardis C. Sabeti, MD, D. Phil. |
Management |
For |
For |
| 1G. |
Election of Director: Mitchell P. Rales |
Management |
For |
For |
| 1H. |
Election of Director: Steven M. Rales |
Management |
For |
For |
| 1I. |
Election of Director: John T. Schwieters |
Management |
For |
For |
| 1J. |
Election of Director: Alan G. Spoon |
Management |
For |
For |
| 1K. |
Election of Director: Raymond C. Stevens, Ph.D. |
Management |
For |
For |
| 1L. |
Election of Director: Elias A. Zerhouni, MD |
Management |
For |
For |
| 2. |
To ratify the selection of Ernst & Young LLP as Danaher's independent registered public accounting firm for the year ending December 31, 2020 |
Management |
For |
For |
| 3. |
To approve on an advisory basis the Company's named executive officer compensation |
Management |
For |
For |
| 4. |
To act upon a shareholder proposal requesting that Danaher amend its governing documents to reduce the percentage of shares required for shareholders to call a special meeting of shareholders from 25% to 10% |
Shareholder |
Against |
For |
DECIPHER BIOSCIENCES, INC.
| Security |
N/A |
Meeting Type |
Written Consent |
| Ticker Symbol |
N/A |
Meeting Date |
16-Sep-2019 |
| Record Date |
N/A |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
Amendment of 2018 Equity Incentive Plan |
Management |
For |
For |
| 2 . |
General Authorizing Resolution |
Management |
For |
For |
DECIPHER BIOSCIENCES, INC.
| Security |
N/A |
Meeting Type |
Written Consent |
| Ticker Symbol |
N/A |
Meeting Date |
14-May-2020 |
| Record Date |
N/A |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
Amendment and Restatement of Certification of Incorporation |
Management |
For |
For |
| 2. |
Series 4 Preferred Stock and Note Financing |
Management |
For |
For |
| 3. |
Amendment of 2018 Equity Incentive Plan |
Management |
For |
For |
| 4. |
General Authorizing Resolution |
Management |
For |
For |
DECIPHER PHARMACEUTICALS, INC.
| Security |
24344T101 |
Meeting Type |
Annual |
| Ticker Symbol |
DCPH |
Meeting Date |
10-Jun-2020 |
| Record Date |
13-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Patricia L. Allen |
For |
For |
|
2 |
Edward J. Benz, Jr., MD |
For |
For |
|
3 |
Dennis L. Walsh |
For |
For |
| 2. |
To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2020. |
Management |
For |
For |
DENTSPLY SIRONA INC.
| Security |
24906P109 |
Meeting Type |
Annual |
| Ticker Symbol |
XRAY |
Meeting Date |
20-May-2020 |
| Record Date |
23-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Michael C. Alfano |
Management |
For |
For |
| 1B. |
Election of Director: Eric K. Brandt |
Management |
For |
For |
| 1C. |
Election of Director: Donald M. Casey Jr. |
Management |
For |
For |
| 1D. |
Election of Director: Willie A. Deese |
Management |
For |
For |
| 1E. |
Election of Director: Betsy D. Holden |
Management |
For |
For |
| 1F. |
Election of Director: Arthur D. Kowaloff |
Management |
For |
For |
| 1G. |
Election of Director: Harry M. Kraemer Jr. |
Management |
For |
For |
| 1H. |
Election of Director: Gregory T. Lucier |
Management |
For |
For |
| 1I. |
Election of Director: Francis J. Lunger |
Management |
For |
For |
| 1J. |
Election of Director: Leslie F. Varon |
Management |
For |
For |
| 1K. |
Election of Director: Janet S. Vergis |
Management |
For |
For |
| 2. |
Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accountants for 2020. |
Management |
For |
For |
| 3. |
Approval, by non-binding vote, of the Company's executive compensation. |
Management |
For |
For |
Field: Page; Sequence: 22
Field: /Page
DYNACURE
| Security |
N/A |
Meeting Type |
Annual Meeting |
| Ticker Symbol |
N/A |
Meeting Date |
16-Jun-2020 |
| Record Date |
N/A |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
Waiver of the period and form of prior notice |
Management |
For |
For |
| 2 . |
Approval of the financial statements for the financial year ended on December 31, 2019; Discharge to the Chairman for his duties during the past financial year |
Management |
For |
For |
| 3 . |
Allocation of the result of the financial year ended on December 31, 2019 |
Management |
For |
For |
| 4 . |
Review and approval of the Statutory Auditors' special report on the agreements referred to in Article L. 227-10 of the French commercial code |
Management |
For |
For |
| 5 . |
Renewal of the terms of office of Brett Monia, Raphael Wisniewski, Remi Droller and Georges Gemayel, in their capacity as members of the Supervisory Board |
Management |
For |
For |
| 6 . |
Acknowledgement of the resignation of Caroline Dreyer and Philippe Guinot from their duties as observers of the Supervisory Board and appointment of new observers of the Supervisory Board |
Management |
For |
For |
| 7 . |
Powers to carry out formalities |
Management |
For |
For |
EDITAS MEDICINE, INC.
| Security |
28106W103 |
Meeting Type |
Annual |
| Ticker Symbol |
EDIT |
Meeting Date |
10-Jun-2020 |
| Record Date |
15-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
James C. Mullen |
For |
For |
|
2 |
Akshay Vaishnaw, M.D. |
For |
For |
| 2. |
To approve, on an advisory basis, named executive officer compensation. |
Management |
For |
For |
| 3. |
To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
EDWARDS LIFESCIENCES CORPORATION
| Security |
28176E108 |
Meeting Type |
Annual |
| Ticker Symbol |
EW |
Meeting Date |
07-May-2020 |
| Record Date |
13-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Michael A. Mussallem |
Management |
For |
For |
| 1B. |
Election of Director: Kieran T. Gallahue |
Management |
For |
For |
| 1C. |
Election of Director: Leslie S. Heisz |
Management |
For |
For |
| 1D. |
Election of Director: William J. Link, Ph.D. |
Management |
For |
For |
| 1E. |
Election of Director: Steven R. Loranger |
Management |
For |
For |
| 1F. |
Election of Director: Martha H. Marsh |
Management |
For |
For |
| 1G. |
Election of Director: Ramona Sequeira |
Management |
For |
For |
| 1H. |
Election of Director: Nicholas J. Valeriani |
Management |
For |
For |
| 2. |
ADVISORY VOTE TO APPROVE COMPENSATION OF NAMED EXECUTIVE OFFICERS. |
Management |
For |
For |
| 3. |
APPROVAL OF THE 2020 NONEMPLOYEE DIRECTORS STOCK INCENTIVE PROGRAM. |
Management |
For |
For |
| 4. |
APPROVAL OF AMENDMENT OF THE CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FOR THE PURPOSE OF EFFECTING A THREE-FOR-ONE STOCK SPLIT. |
Management |
For |
For |
| 5. |
RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM. |
Management |
For |
For |
| 6. |
ADVISORY VOTE ON A STOCKHOLDER PROPOSAL REGARDING ACTION BY WRITTEN CONSENT. |
Shareholder |
Against |
For |
EIDOS THERAPEUTICS INC.
| Security |
28249H104 |
Meeting Type |
Annual |
| Ticker Symbol |
EIDX |
Meeting Date |
27-May-2020 |
| Record Date |
01-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Neil Kumar, Ph.D. |
For |
For |
|
2 |
Eric Aguiar, M.D. |
For |
For |
|
3 |
William Lis |
For |
For |
|
4 |
Ali Satvat |
For |
For |
|
5 |
Rajeev Shah |
For |
For |
|
6 |
Uma Sinha, Ph.D. |
For |
For |
| 2. |
To |
|
|
|
| ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020. |
Management |
For |
For |
|
| 3. |
To approve an amendment and restatement of the Company's Amended and Restated 2018 Stock Option and Incentive Plan to, among other things, increase the number of shares of common stock reserved for issuance thereunder by 1,500,000 shares. |
Management |
For |
For |
Field: Page; Sequence: 23
Field: /Page
ELI LILLY AND COMPANY
| Security |
532457108 |
Meeting Type |
Annual |
| Ticker Symbol |
LLY |
Meeting Date |
04-May-2020 |
| Record Date |
09-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: M. L. Eskew |
Management |
For |
For |
| 1B. |
Election of Director: W. G. Kaelin, Jr. |
Management |
For |
For |
| 1C. |
Election of Director: D. A. Ricks |
Management |
For |
For |
| 1D. |
Election of Director: M. S. Runge |
Management |
For |
For |
| 1E. |
Election of Director: K. Walker |
Management |
For |
For |
| 2. |
Approval, by non-binding vote, of the compensation paid to the company's named executive officers. |
Management |
For |
For |
| 3. |
Ratification of Ernst & Young LLP as the independent auditor for 2020. |
Management |
For |
For |
| 4. |
Approve amendments to the Articles of Incorporation to eliminate the classified board structure. |
Management |
For |
For |
| 5. |
Approve amendments to the Articles of Incorporation to eliminate supermajority voting provisions. |
Management |
For |
For |
| 6. |
Shareholder proposal to disclose direct and indirect lobbying activities and expenditures. |
Shareholder |
Against |
For |
| 7. |
Shareholder proposal to publish a report on the effectiveness of the forced swim test. |
Shareholder |
Against |
For |
| 8. |
Shareholder proposal to amend the bylaws to require an independent board chair. |
Shareholder |
For |
Against |
| 9. |
Shareholder proposal on board diversity requesting disclosures of specific minimum qualifications and board nominee skills, experience, and ideological perspective. |
Shareholder |
Against |
For |
| 10. |
Shareholder proposal to publish feasibility report on incorporating public concern over drug prices into senior executive compensation arrangements. |
Shareholder |
Against |
For |
| 11. |
Shareholder proposal to implement a bonus deferral policy. |
Shareholder |
Against |
For |
| 12. |
Shareholder proposal to disclose clawbacks on executive incentive compensation due to misconduct. |
Shareholder |
Against |
For |
ENDO INTERNATIONAL PLC
| Security |
G30401106 |
Meeting Type |
Annual |
| Ticker Symbol |
ENDP |
Meeting Date |
11-Jun-2020 |
| Record Date |
13-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Paul V. Campanelli |
Management |
For |
For |
| 1B. |
Election of Director: Blaise Coleman |
Management |
For |
For |
| 1C. |
Election of Director: Mark G. Barberio |
Management |
For |
For |
| 1D. |
Election of Director: Shane M. Cooke |
Management |
For |
For |
| 1E. |
Election of Director: Nancy J. Hutson, Ph.D. |
Management |
For |
For |
| 1F. |
Election of Director: Michael Hyatt |
Management |
For |
For |
| 1G. |
Election of Director: Roger H. Kimmel |
Management |
For |
For |
| 1H. |
Election of Director: William P. Montague |
Management |
For |
For |
| 2. |
To approve, by advisory vote, named executive officer compensation. |
Management |
For |
For |
| 3. |
To approve the Endo International plc Amended and Restated 2015 Stock Incentive Plan. |
Management |
For |
For |
| 4. |
To renew the Board's existing authority to issue shares under Irish law. |
Management |
For |
For |
| 5. |
To renew the Board's existing authority to opt-out of statutory pre-emption rights under Irish law. |
Management |
For |
For |
| 6. |
To approve the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2020 and to authorize the Board of Directors, acting through the Audit Committee, to determine the independent registered public accounting firm's remuneration. |
Management |
For |
For |
Field: Page; Sequence: 24
Field: /Page
EPIZYME, INC.
| Security |
29428V104 |
Meeting Type |
Annual |
| Ticker Symbol |
EPZM |
Meeting Date |
29-May-2020 |
| Record Date |
07-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Andrew R. Allen, MD PhD |
For |
For |
|
2 |
Kenneth Bate |
For |
For |
|
3 |
Robert B. Bazemore, Jr. |
For |
For |
|
4 |
Victoria Richon, Ph.D. |
For |
For |
| 2. |
Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 3. |
Advisory Vote on Executive Compensation. |
Management |
For |
For |
| 4. |
Approval of an amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 125,000,000 to 150,000,000. |
Management |
For |
For |
ESPERION THERAPEUTICS INC
| Security |
29664W105 |
Meeting Type |
Annual |
| Ticker Symbol |
ESPR |
Meeting Date |
28-May-2020 |
| Record Date |
31-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Class I Director: Daniel Janney |
Management |
For |
For |
| 1B. |
Election of Class I Director: Tim M. Mayleben |
Management |
For |
For |
| 1C. |
Election of Class I Director: Mark E. McGovern, M.D., FACC, FACP |
Management |
For |
For |
| 1D. |
Election of Class I Director: Tracy M. Woody |
Management |
For |
For |
| 2. |
To approve the advisory resolution on the compensation of our named executive officers |
Management |
For |
For |
| 3. |
To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020 |
Management |
For |
For |
| 4. |
To approve the 2020 Employee Stock Purchase Plan |
Management |
For |
For |
EVOLENT HEALTH, INC.
| Security |
30050B101 |
Meeting Type |
Annual |
| Ticker Symbol |
EVH |
Meeting Date |
09-Jun-2020 |
| Record Date |
15-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1a. |
Election of Class II Director: Bridget Duffy |
Management |
For |
For |
| 1b. |
Election of Class II Director: Diane Holder |
Management |
For |
For |
| 1c. |
Election of Class II Director: Michael D'Amato |
Management |
For |
For |
| 2. |
Proposal to ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 3. |
Proposal to approve the compensation of our named executive officers for 2019 on an advisory basis. |
Management |
For |
For |
EXELIXIS, INC.
| Security |
30161Q104 |
Meeting Type |
Annual |
| Ticker Symbol |
EXEL |
Meeting Date |
20-May-2020 |
| Record Date |
23-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Charles Cohen, Ph.D. |
Management |
For |
For |
| 1B. |
Election of Director: Carl B. Feldbaum, Esq. |
Management |
For |
For |
| 1C. |
Election of Director: Maria C. Freire, Ph.D. |
Management |
For |
For |
| 1D. |
Election of Director: Alan M. Garber, M.D., Ph.D. |
Management |
For |
For |
| 1E. |
Election of Director: Vincent T. Marchesi, M.D., Ph.D. |
Management |
For |
For |
| 1F. |
Election of Director: Michael M. Morrissey, Ph.D. |
Management |
For |
For |
| 1G. |
Election of Director: Stelios Papadopoulos, Ph.D. |
Management |
For |
For |
| 1H. |
Election of Director: George Poste, DVM, Ph.D., FRS |
Management |
For |
For |
| 1I. |
Election of Director: Julie Anne Smith |
Management |
For |
For |
| 1J. |
Election of Director: Lance Willsey, M.D. |
Management |
For |
For |
| 1K. |
Election of Director: Jack L. Wyszomierski |
Management |
For |
For |
| 2. |
To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis' independent registered public accounting firm for the fiscal year ending January 1, 2021. |
Management |
For |
For |
| 3. |
To amend and restate the Exelixis 2017 Equity Incentive Plan to, among other things, increase the number of shares authorized for issuance by 21,000,000 shares. |
Management |
For |
For |
| 4. |
To approve, on an advisory basis, the compensation of Exelixis' named executive officers, as disclosed in the accompanying Proxy Statement. |
Management |
For |
For |
Field: Page; Sequence: 25
Field: /Page
FATE THERAPEUTICS, INC.
| Security |
31189P102 |
Meeting Type |
Annual |
| Ticker Symbol |
FATE |
Meeting Date |
01-May-2020 |
| Record Date |
06-Mar-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Robert S Epstein MD M.S |
For |
For |
|
2 |
John D Mendlein PhD. JD |
For |
For |
|
3 |
Karin Jooss, Ph.D. |
For |
For |
| 2. |
To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020. |
Management |
For |
For |
| 3. |
To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement. |
Management |
For |
For |
FIBROGEN, INC.
| Security |
31572Q808 |
Meeting Type |
Annual |
| Ticker Symbol |
FGEN |
Meeting Date |
04-Jun-2020 |
| Record Date |
09-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Class III Director to hold office until the 2023 Annual Meeting of Stockholders: Enrique Conterno |
Management |
For |
For |
| 1B. |
Election of Class III Director to hold office until the 2023 Annual Meeting of Stockholders: Thomas F. Kearns, Jr. |
Management |
For |
For |
| 1C. |
Election of Class III Director to hold office until the 2023 Annual Meeting of Stockholders: Kalevi Kurkijärvi, Ph.D. |
Management |
For |
For |
| 1D. |
Election of Class III Director to hold office until the 2023 Annual Meeting of Stockholders: Gerald Lema |
Management |
For |
For |
| 2. |
To approve, on an advisory basis, the compensation of FibroGen's named executive officers, as disclosed in the proxy statement. |
Management |
For |
For |
| 3. |
To ratify the selection of PricewaterhouseCoopers LLP by the Audit Committee of the Board of Directors as the independent registered public accounting firm of FibroGen for the year ending December 31, 2020. |
Management |
For |
For |
Field: Page; Sequence: 26
Field: /Page
FOAMIX PHARMACEUTICALS LTD
| Security |
M46135105 |
Meeting Type |
Special |
| Ticker Symbol |
FOMX |
Meeting Date |
06-Feb-2020 |
| Record Date |
06-Jan-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
Approval and adoption of (i) the Agreement and Plan of Merger dated November 10, 2019 (as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of December 4, 2019, and as may be amended from time to time, the "Merger Agreement"), by and among Menlo Therapeutics Inc. ("Menlo"), Giants Merger Subsidiary Ltd., an Israeli company and a wholly-owned subsidiary of Menlo ("Merger Sub") and Foamix Pharmaceuticals Ltd. ("Foamix"); (ii) the merger of Merger Sub with and into ... (due to space limits, see proxy material for full proposal). |
Management |
For |
For |
| 1A. |
By checking the box marked "FOR," the undersigned hereby confirms that he, she, or it is not Menlo, Merger Sub, or a Menlo Related Person. A "Menlo Related Person" is (a) a person holding, directly or indirectly, either (i) 25% or more of the voting rights of Menlo or Merger Sub, or (ii) the right to appoint 25% or more of the directors of Menlo or Merger Sub, (b) a person or entity acting on behalf of Menlo, Merger Sub or a person described in subsection (a) above, or (c) one of such ...(due to space limits, see proxy material for full proposal). |
Management |
For |
|
| 2. |
Approval, on a non-binding, advisory basis, in accordance with the rules under the Securities Exchange Act of 1934, as amended, of certain compensation that may be paid or become payable to the named executive officers of Foamix in connection with the Merger and contemplated by the Merger Agreement. |
Management |
For |
For |
GALAPAGOS N V
| Security |
36315X101 |
Meeting Type |
Special |
| Ticker Symbol |
GLPG |
Meeting Date |
22-Oct-2019 |
| Record Date |
17-Sep-2019 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| S1. |
Appointment of Mr. Daniel O'Day as a director of the company. |
Management |
For |
For |
| S2. |
Appointment of Ms. Linda Higgins as a director of the company. |
Management |
For |
For |
| S3. |
Remuneration of statutory auditor for the financial year ended on 31 December 2017. |
Management |
For |
For |
| E3. |
Approval of the issuance of two warrants for the benefit of Gilead Therapeutics. |
Management |
For |
For |
| E5. |
Renewal |
|
|
|
| of the authorization to the board of directors to increase the share capital within the framework of the authorized capital by up to 20% of the share capital. |
Management |
For |
For |
|
GALAPAGOS N V
| Security |
36315X101 |
Meeting Type |
Annual |
| Ticker Symbol |
GLPG |
Meeting Date |
28-Apr-2020 |
| Record Date |
20-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| A2 |
Acknowledgement and approval of the non-consolidated annual accounts of the Company for the financial year ended on 31 December 2019 and approval of the allocation of the annual result as proposed by the board of directors. |
Management |
For |
For |
| A5. |
Acknowledgement and approval of the remuneration policy. |
Management |
For |
For |
| A6 |
Acknowledgement and approval of the remuneration report. |
Management |
For |
For |
| A7 |
Release from liability to be granted to the directors and the statutory auditor for the performance of their duties in the course of the financial year ended 31 December 2019. |
Management |
For |
For |
| A9 |
Re-appointment of statutory auditor and determination of statutory auditor's remuneration. |
Management |
For |
For |
| A10 |
Re-appointment of Dr. Mary Kerr as a director of the Company. |
Management |
For |
For |
| A11 |
Appointment of Dr. Elisabeth Svanberg as a director of the Company. |
Management |
For |
For |
| A12 |
Remuneration of directors. |
Management |
For |
For |
| A13 |
Offer of subscription rights. |
Management |
For |
For |
| E2 |
Amendment to the Company's purpose. |
Management |
For |
For |
| E3 |
Amendments to the articles of association as a consequence of the newly applicable CCA, the choice for a two-tier board structure and certain other amendments relating to modernization and clean-up of the articles of association. |
Management |
For |
For |
| E4 |
Appointment of the members of the supervisory board. |
Management |
For |
For |
| E5 |
Authorization to the management board to execute the above decisions and to coordinate the articles of association. |
Management |
For |
For |
| E6 |
Proxy Crossroad Bank for Enterprises, counters for enterprises, registers of the enterprise court, administrative agencies and fiscal administrations. |
Management |
For |
For |
Field: Page; Sequence: 27
Field: /Page
GALAPAGOS N V
| Security |
36315X101 |
Meeting Type |
Annual |
| Ticker Symbol |
GLPG |
Meeting Date |
28-Apr-2020 |
| Record Date |
09-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| A2 |
Acknowledgement and approval of the non-consolidated annual accounts of the Company for the financial year ended on 31 December 2019 and approval of the allocation of the annual result as proposed by the board of directors. |
Management |
For |
For |
| A5. |
Acknowledgement and approval of the remuneration policy. |
Management |
For |
For |
| A6 |
Acknowledgement and approval of the remuneration report. |
Management |
For |
For |
| A7 |
Release from liability to be granted to the directors and the statutory auditor for the performance of their duties in the course of the financial year ended 31 December 2019. |
Management |
For |
For |
| A9 |
Re-appointment of statutory auditor and determination of statutory auditor's remuneration. |
Management |
For |
For |
| A10 |
Re-appointment of Dr. Mary Kerr as a director of the Company. |
Management |
For |
For |
| A11 |
Appointment of Dr. Elisabeth Svanberg as a director of the Company. |
Management |
For |
For |
| A12 |
Remuneration of directors. |
Management |
For |
For |
| A13 |
Offer of subscription rights. |
Management |
For |
For |
| E2 |
Amendment to the Company's purpose. |
Management |
For |
For |
| E3 |
Amendments to the articles of association as a consequence of the newly applicable CCA, the choice for a two-tier board structure and certain other amendments relating to modernization and clean-up of the articles of association. |
Management |
For |
For |
| E4 |
Appointment of the members of the supervisory board. |
Management |
For |
For |
| E5 |
Authorization to the management board to execute the above decisions and to coordinate the articles of association. |
Management |
For |
For |
| E6 |
Proxy Crossroad Bank for Enterprises, counters for enterprises, registers of the enterprise court, administrative agencies and fiscal administrations. |
Management |
For |
For |
GALERA THERAPEUTICS, INC.
| Security |
N/A |
Meeting Type |
Written Consent |
| Ticker Symbol |
N/A |
Meeting Date |
9-Jul-2019 |
| Record Date |
N/A |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
Election of Lawrence Alleva to the Board of Directors |
Management |
For |
For |
| 2. |
General Enabling Resolutions |
Management |
For |
For |
GALERA THERAPEUTICS, INC.
| Security |
N/A |
Meeting Type |
Written Consent |
| Ticker Symbol |
N/A |
Meeting Date |
16-Oct-2019 |
| Record Date |
N/A |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
Form of Lock-Up Agreement |
Management |
For |
For |
Field: Page; Sequence: 28
Field: /Page
GALERA THERAPEUTICS, INC.
| Security |
36338D108 |
Meeting Type |
Annual |
| Ticker Symbol |
GRTX |
Meeting Date |
09-Jun-2020 |
| Record Date |
16-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Michael Powell, Ph.D. |
For |
For |
|
2 |
Linda West |
For |
For |
| 2. |
To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
GENMAB A S
| Security |
372303206 |
Meeting Type |
Annual |
| Ticker Symbol |
GMAB |
Meeting Date |
26-Mar-2020 |
| Record Date |
21-Feb-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 2. |
Adoption of the audited Annual Report and discharge of the Board of Directors and the Executive Management. |
Management |
For |
For |
| 3. |
Decision as to the distribution of profit according to the adopted Annual Report. |
Management |
For |
For |
| 4A. |
Re-election of Director: Deirdre P. Connelly |
Management |
For |
For |
| 4B. |
Re-election of Director: Pernille Erenbjerg |
Management |
For |
For |
| 4C. |
Re-election of Director: Rolf Hoffmann |
Management |
For |
For |
| 4D. |
Re-election of Director: Dr. Paolo Paoletti |
Management |
For |
For |
| 4E. |
Re-election of Director: Dr. Anders Gersel Pedersen |
Management |
For |
For |
| 4F. |
Election of Director: Jonathan Peacock |
Management |
For |
For |
| 5. |
Re-election of auditor: PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab. |
Management |
For |
For |
| 6A. |
Proposals from the Board of Directors: Adoption of the Remuneration Policy for the Board of Directors and the Executive Management. |
Management |
For |
For |
| 6B. |
Proposals from the Board of Directors: Approval of the Board of Directors' remuneration for 2020. |
Management |
For |
For |
| 6C. |
Proposals from the Board of Directors: Amendment of Article 6 (provider of share registration services). |
Management |
For |
For |
| 7. |
Authorization of the chairman of the General Meeting to register resolutions passed by the General Meeting. |
Management |
For |
For |
GILEAD SCIENCES, INC.
| Security |
375558103 |
Meeting Type |
Annual |
| Ticker Symbol |
GILD |
Meeting Date |
06-May-2020 |
| Record Date |
13-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Jacqueline K. Barton, Ph.D. |
Management |
For |
For |
| 1B. |
Election of Director: Sandra J. Horning, M.D. |
Management |
For |
For |
| 1C. |
Election of Director: Kelly A. Kramer |
Management |
For |
For |
| 1D. |
Election of Director: Kevin E. Lofton |
Management |
For |
For |
| 1E. |
Election of Director: Harish Manwani |
Management |
For |
For |
| 1F. |
Election of Director: Daniel P. O'Day |
Management |
For |
For |
| 1G. |
Election of Director: Richard J. Whitley, M.D. |
Management |
For |
For |
| 1H. |
Election of Director: Per Wold-Olsen |
Management |
For |
For |
| 2. |
To ratify the selection of Ernst & Young LLP by the Audit Committee of the Board of Directors as the independent registered public accounting firm of Gilead for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 3. |
To |
|
|
|
| approve, on an advisory basis, the compensation of our Named Executive |
|
|
|
|
| Officers as presented in the Proxy Statement. |
Management |
For |
For |
|
| 4. |
To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board adopt a policy that the Chairperson of the Board of Directors be an independent director. |
Shareholder |
For |
Against |
| 5. |
To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board eliminate the ownership threshold for stockholders to request a record date to take action by written consent. |
Shareholder |
For |
Against |
Field: Page; Sequence: 29
Field: /Page
Field: Split-Segment; Name: 3
GLOBAL BLOOD THERAPEUTICS, INC.
| Security |
37890U108 |
Meeting Type |
Annual |
| Ticker Symbol |
GBT |
Meeting Date |
17-Jun-2020 |
| Record Date |
22-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Willie L. Brown, Jr. |
For |
For |
|
2 |
Philip A. Pizzo, M.D. |
For |
For |
|
3 |
Wendy Yarno |
For |
For |
| 2. |
Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement. |
Management |
For |
For |
| 3. |
Ratification of the appointment of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020. |
Management |
For |
For |
GUARDANT HEALTH, INC.
| Security |
40131M109 |
Meeting Type |
Annual |
| Ticker Symbol |
GH |
Meeting Date |
12-Jun-2020 |
| Record Date |
20-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Class II Director: Ian Clark |
Management |
For |
For |
| 1B. |
Election of Class II Director: Samir Kaul |
Management |
For |
For |
| 2. |
Ratification of the appointment of Ernst & Young LLP as Guardant Health, Inc.'s independent registered public accounting firm for the year ending December 31, 2020. |
Management |
For |
For |
| 3. |
Advisory vote on the frequency of stockholder advisory votes regarding the compensation of our named executive officers. |
Management |
1 Year |
For |
GW PHARMACEUTICALS PLC
| Security |
36197T103 |
Meeting Type |
Annual |
| Ticker Symbol |
GWPH |
Meeting Date |
26-May-2020 |
| Record Date |
31-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
To re-elect Dr. Geoffrey W. Guy as a Director |
Management |
For |
For |
| 2. |
To re-elect Cabot Brown as a Director |
Management |
For |
For |
| 3. |
To approve the 2020 Long Term Incentive Plan |
Management |
For |
For |
| 4. |
To approve the Directors' Remuneration Report |
Management |
For |
For |
| 5. |
To approve the compensation of the Company's named executive officers |
Management |
For |
For |
| 6. |
To ratify the appointment of Deloitte and Touche LLP as the Company's US public accounting firm |
Management |
For |
For |
| 7. |
To re-appoint Deloitte LLP as the UK Auditor |
Management |
For |
For |
| 8. |
To authorise the Directors to determine the Auditors' remuneration |
Management |
For |
For |
| 9. |
To receive, consider and adopt the Directors' and Auditors' Reports and Statement of Accounts for the 12- month period ended 31 December 2019 and note that the Directors do not recommend the payment of a dividend |
Management |
For |
For |
| 10. |
To authorise the Directors to allot shares pursuant to Section 551 of the Companies Act 2006 (the "2006 Act") such authority to be valid up to 26 May 2021 |
Management |
For |
For |
| 11. |
Subject to the passing of Resolution 10, to authorise the Directors to allot equity securities, under Section 570 of the 2006 Act as if Section 561(1) of the 2006 Act did not apply to such allotment |
Management |
For |
For |
Field: Page; Sequence: 30
Field: /Page
HCA HEALTHCARE, INC.
| Security |
40412C101 |
Meeting Type |
Annual |
| Ticker Symbol |
HCA |
Meeting Date |
01-May-2020 |
| Record Date |
09-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Thomas F. Frist III |
Management |
For |
For |
| 1B. |
Election of Director: Samuel N. Hazen |
Management |
For |
For |
| 1C. |
Election of Director: Meg G. Crofton |
Management |
For |
For |
| 1D. |
Election of Director: Robert J. Dennis |
Management |
For |
For |
| 1E. |
Election of Director: Nancy-Ann DeParle |
Management |
For |
For |
| 1F. |
Election of Director: William R. Frist |
Management |
For |
For |
| 1G. |
Election of Director: Charles O. Holliday, Jr. |
Management |
For |
For |
| 1H. |
Election of Director: Michael W. Michelson |
Management |
For |
For |
| 1I. |
Election of Director: Wayne J. Riley, M.D. |
Management |
For |
For |
| 2. |
To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2020. |
Management |
For |
For |
| 3. |
Advisory vote to approve named executive officer compensation. |
Management |
For |
For |
| 4. |
To approve the 2020 Stock Incentive Plan for Key Employees of HCA Healthcare, Inc. and its Affiliates. |
Management |
For |
For |
| 5. |
To approve an amendment to our amended and restated certificate of incorporation to allow stockholders owning an aggregate of 15% of our outstanding common stock to request special meetings of stockholders. |
Management |
For |
For |
| 6. |
Stockholder proposal, if properly presented at the meeting, requesting that the Board of Directors take the steps necessary to allow stockholders to act by written consent. |
Shareholder |
Against |
For |
HERON THERAPEUTICS, INC.
| Security |
427746102 |
Meeting Type |
Annual |
| Ticker Symbol |
HRTX |
Meeting Date |
17-Jun-2020 |
| Record Date |
20-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Kevin Tang |
Management |
For |
For |
| 1B. |
Election of Director: Barry Quart, Pharm.D. |
Management |
For |
For |
| 1C. |
Election of Director: Stephen Davis |
Management |
For |
For |
| 1D. |
Election of Director: Craig Johnson |
Management |
For |
For |
| 1E. |
Election of Director: Kimberly Manhard |
Management |
For |
For |
| 1F. |
Election of Director: John Poyhonen |
Management |
For |
For |
| 1G. |
Election of Director: Christian Waage |
Management |
For |
For |
| 2. |
To ratify the appointment of OUM & Co. LLP as the Company's independent registered public accounting firm for the year ending December 31, 2020. |
Management |
For |
For |
| 3. |
To approve, on an advisory basis, compensation paid to the Company's Named Executive Officers during the year ended December 31, 2019. |
Management |
For |
For |
HOLOGIC, INC.
| Security |
436440101 |
Meeting Type |
Annual |
| Ticker Symbol |
HOLX |
Meeting Date |
05-Mar-2020 |
| Record Date |
08-Jan-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Stephen P. MacMillan |
For |
For |
|
2 |
Sally W. Crawford |
For |
For |
|
3 |
Charles J. Dockendorff |
For |
For |
|
4 |
Scott T. Garrett |
For |
For |
|
5 |
Ludwig N. Hantson |
For |
For |
|
6 |
Namal Nawana |
For |
For |
|
7 |
Christiana Stamoulis |
For |
For |
|
8 |
Amy M. Wendell |
For |
For |
| 2. |
A non-binding advisory resolution to approve executive compensation. |
Management |
For |
For |
| 3. |
Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for fiscal 2020. |
Management |
For |
For |
HORIZON THERAPEUTICS PLC
| Security |
G46188101 |
Meeting Type |
Annual |
| Ticker Symbol |
HZNP |
Meeting Date |
30-Apr-2020 |
| Record Date |
25-Feb-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Class III Director: Gino Santini |
Management |
For |
For |
| 1B. |
Election of Class III Director: James Shannon, M.D. |
Management |
For |
For |
| 1C. |
Election of Class III Director: Timothy Walbert |
Management |
For |
For |
| 2. |
Approval of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2020 and authorization of the Audit Committee to determine the auditors' remuneration. |
Management |
For |
For |
| 3. |
Approval, on an advisory basis, of the compensation of our named executive officers, as disclosed in the Proxy Statement. |
Management |
For |
For |
| 4. |
Authorization |
|
|
|
| for us and/or any of our subsidiaries to make market purchases or overseas market purchases of our ordinary shares. |
Management |
For |
For |
|
| 5. |
Approval of the 2020 Equity Incentive Plan. |
Management |
For |
For |
| 6. |
Approval of the 2020 Employee Share Purchase Plan. |
Management |
For |
For |
Field: Page; Sequence: 31
Field: /Page
HUMANA INC.
| Security |
444859102 |
Meeting Type |
Annual |
| Ticker Symbol |
HUM |
Meeting Date |
23-Apr-2020 |
| Record Date |
24-Feb-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Kurt J. Hilzinger |
Management |
For |
For |
| 1B. |
Election of Director: Frank J. Bisignano |
Management |
For |
For |
| 1C. |
Election of Director: Bruce D. Broussard |
Management |
For |
For |
| 1D. |
Election of Director: Frank A. D'Amelio |
Management |
For |
For |
| 1E. |
Election of Director: W. Roy Dunbar |
Management |
For |
For |
| 1F. |
Election of Director: Wayne A. I. Frederick, M.D. |
Management |
For |
For |
| 1G. |
Election of Director: John W. Garratt |
Management |
For |
For |
| 1H. |
Election of Director: David A. Jones, Jr. |
Management |
For |
For |
| 1I. |
Election of Director: Karen W. Katz |
Management |
For |
For |
| 1J. |
Election of Director: William J. McDonald |
Management |
For |
For |
| 1K. |
Election of Director: James J. O'Brien |
Management |
For |
For |
| 1L. |
Election of Director: Marissa T. Peterson |
Management |
For |
For |
| 2. |
The ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm. |
Management |
For |
For |
| 3. |
Non-binding advisory vote for the approval of the compensation of the named executive officers as disclosed in the 2020 proxy statement. |
Management |
For |
For |
IDEXX LABORATORIES, INC.
| Security |
45168D104 |
Meeting Type |
Annual |
| Ticker Symbol |
IDXX |
Meeting Date |
06-May-2020 |
| Record Date |
09-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Rebecca M. Henderson, PhD |
Management |
For |
For |
| 1B. |
Election of Director: Lawrence D. Kingsley |
Management |
For |
For |
| 1C. |
Election of Director: Sophie V. Vandebroek, PhD |
Management |
For |
For |
| 2. |
Ratification of Appointment of Independent Registered Public Accounting Firm. To ratify the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year (Proposal Two). |
Management |
For |
For |
| 3. |
Advisory Vote on Executive Compensation. To approve a nonbinding advisory resolution on the Company's executive compensation (Proposal Three). |
Management |
For |
For |
ILLUMINA, INC.
| Security |
452327109 |
Meeting Type |
Annual |
| Ticker Symbol |
ILMN |
Meeting Date |
27-May-2020 |
| Record Date |
30-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Caroline Dorsa |
Management |
For |
For |
| 1B. |
Election of Director: Robert S. Epstein, M.D. |
Management |
For |
For |
| 1C. |
Election of Director: Scott Gottlieb, M.D. |
Management |
For |
For |
| 1D. |
Election of Director: Philip W. Schiller |
Management |
For |
For |
| 2. |
To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending January 3, 2021. |
Management |
For |
For |
| 3. |
To approve, on an advisory basis, the compensation of the named executive officers as disclosed in the Proxy Statement. |
Management |
For |
For |
| 4. |
To approve, on an advisory basis, a stockholder proposal regarding political disclosures. |
Shareholder |
Against |
For |
Field: Page; Sequence: 32
Field: /Page
ILLUMINOSS MEDICAL, INC.
| Security |
N/A |
Meeting Type |
Written Consent |
| Ticker Symbol |
N/A |
Meeting Date |
1-Jul-19 |
| Record Date |
N/A |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
Amendment to Sixth Amended and Restated Certification of Incorporation |
Management |
For |
For |
| 2. |
Amendment No. 5 to Amended and Restated Secured Note and Warrant Purchase Agreement |
Management |
For |
For |
| 3. |
General Authorizing Resolution |
Management |
For |
For |
ILLUMINOSS MEDICAL, INC.
| Security |
N/A |
Meeting Type |
Written Consent |
| Ticker Symbol |
N/A |
Meeting Date |
21-Apr-20 |
| Record Date |
N/A |
Holding Recon Date |
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
Merger; Agreement and Plan of Merger |
Management |
For |
For |
| 2. |
General Ratification and Authorization |
Management |
For |
For |
IMMUNOGEN, INC.
| Security |
45253H101 |
Meeting Type |
Annual |
| Ticker Symbol |
IMGN |
Meeting Date |
17-Jun-2020 |
| Record Date |
13-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
To fix the number of members of the Board of Directors at seven (7). |
Management |
For |
For |
| 2. |
DIRECTOR |
Management |
|
|
|
1 |
Stephen C. McCluski |
For |
For |
|
2 |
Richard J. Wallace |
For |
For |
|
3 |
Mark Goldberg, MD |
For |
For |
|
4 |
Dean J. Mitchell |
For |
For |
|
5 |
Kristine Peterson |
For |
For |
|
6 |
Mark J. Enyedy |
For |
For |
|
7 |
Stuart A. Arbuckle |
For |
For |
| 3. |
To approve an amendment to our Restated Articles of Organization to increase the number of authorized shares of common stock from 200,000,000 to 300,000,000. |
Management |
For |
For |
| 4. |
To approve, on an advisory basis, the compensation paid to our named executive officers, as disclosed in our proxy statement. |
Management |
For |
For |
IMMUNOMEDICS, INC.
| Security |
452907108 |
Meeting Type |
Annual |
| Ticker Symbol |
IMMU |
Meeting Date |
18-Jun-2020 |
| Record Date |
24-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1.1 |
Election of Director: Dr. Behzad Aghazadeh |
Management |
For |
For |
| 1.2 |
Election of Director: Robert Azelby |
Management |
For |
For |
| 1.3 |
Election of Director: Dr. Charles M. Baum |
Management |
For |
For |
| 1.4 |
Election of Director: Scott Canute |
Management |
For |
For |
| 1.5 |
Election of Director: Barbara G. Duncan |
Management |
For |
For |
| 1.6 |
Election of Director: Peter Barton Hutt |
Management |
For |
For |
| 1.7 |
Election of Director: Dr. Khalid Islam |
Management |
For |
For |
| 1.8 |
Election of Director: Harout Semerjian |
Management |
For |
For |
| 2. |
Proposal to approve the compensation of our named executive officers. |
Management |
For |
For |
| 3. |
Proposal to approve the amendment and restatement of the Company's certificate of incorporation. |
Management |
For |
For |
| 4. |
Proposal to approve the amendment and restatement of the Company's 2014 Long-Term Incentive Plan. |
Management |
For |
For |
| 5. |
Proposal to approve and adopt the Company's 2020 Employee Stock Purchase Plan. |
Management |
For |
For |
| 6. |
Proposal to ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
Field: Page; Sequence: 33
Field: /Page
INCYTE CORPORATION
| Security |
45337C102 |
Meeting Type |
Annual |
| Ticker Symbol |
INCY |
Meeting Date |
26-May-2020 |
| Record Date |
01-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1.1 |
Election of Director: Julian C. Baker |
Management |
For |
For |
| 1.2 |
Election of Director: Jean-Jacques Bienaimé |
Management |
For |
For |
| 1.3 |
Election of Director: Paul J. Clancy |
Management |
For |
For |
| 1.4 |
Election of Director: Wendy L. Dixon |
Management |
For |
For |
| 1.5 |
Election of Director: Jacqualyn A. Fouse |
Management |
For |
For |
| 1.6 |
Election of Director: Paul A. Friedman |
Management |
For |
For |
| 1.7 |
Election of Director: Edmund P. Harrigan |
Management |
For |
For |
| 1.8 |
Election of Director: Katherine A. High |
Management |
For |
For |
| 1.9 |
Election of Director: Hervé Hoppenot |
Management |
For |
For |
| 2. |
To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. |
Management |
For |
For |
| 3. |
To |
|
|
|
| approve an amendment to the Company's 1997 Employee Stock Purchase Plan. |
Management |
For |
For |
|
| 4. |
To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2020. |
Management |
For |
For |
| 5. |
To vote on a stockholder proposal, if properly presented, described in more detail in the proxy statement. |
Shareholder |
Against |
For |
INOGEN, INC.
| Security |
45780L104 |
Meeting Type |
Annual |
| Ticker Symbol |
INGN |
Meeting Date |
11-May-2020 |
| Record Date |
13-Mar-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Heath Lukatch, Ph.D. |
For |
For |
|
2 |
Raymond Huggenberger |
For |
For |
| 2. |
To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending December 31, 2020. |
Management |
For |
For |
| 3. |
Approval on an advisory basis of our executive compensation for the fiscal year ended December 31, 2019. |
Management |
For |
For |
INSMED INCORPORATED
| Security |
457669307 |
Meeting Type |
Annual |
| Ticker Symbol |
INSM |
Meeting Date |
12-May-2020 |
| Record Date |
18-Mar-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Clarissa Desjardins PhD |
For |
For |
|
2 |
David W.J. McGirr |
For |
For |
|
3 |
E. McKee Anderson |
For |
For |
| 2. |
Advisory vote on the 2019 compensation of our named executive officers. |
Management |
For |
For |
| 3. |
Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for Insmed Incorporated for the year ending December 31, 2020. |
Management |
For |
For |
| 4. |
Approval of an amendment to the Insmed Incorporated 2019 Incentive Plan. |
Management |
For |
For |
INTELLIA THERAPEUTICS, INC.
| Security |
45826J105 |
Meeting Type |
Annual |
| Ticker Symbol |
NTLA |
Meeting Date |
18-Jun-2020 |
| Record Date |
20-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Jean-François Formela |
For |
For |
|
2 |
Jesse Goodman, M.D MPH |
For |
For |
| 2. |
Ratification of the appointment of Deloitte & Touche LLP as Intellia's independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 3. |
Approve, on an advisory basis, the compensation of the named executive officers. |
Management |
For |
For |
Field: Page; Sequence: 34
Field: /Page
INTERCEPT PHARMACEUTICALS, INC.
| Security |
45845P108 |
Meeting Type |
Annual |
| Ticker Symbol |
ICPT |
Meeting Date |
28-May-2020 |
| Record Date |
06-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Paolo Fundarò |
Management |
For |
For |
| 1B. |
Election of Director: Mark Pruzanski, M.D. |
Management |
For |
For |
| 1C. |
Election of Director: Srinivas Akkaraju, M.D., Ph.D. |
Management |
For |
For |
| 1D. |
Election of Director: Luca Benatti, Ph.D. |
Management |
For |
For |
| 1E. |
Election of Director: Daniel Bradbury |
Management |
For |
For |
| 1F. |
Election of Director: Keith Gottesdiener, M.D. |
Management |
For |
For |
| 1G. |
Election of Director: Nancy Miller-Rich |
Management |
For |
For |
| 1H. |
Election of Director: Gino Santini |
Management |
For |
For |
| 1I. |
Election of Director: Glenn Sblendorio |
Management |
For |
For |
| 1J. |
Election of Director: Daniel Welch |
Management |
For |
For |
| 2. |
FOR the approval of an amendment to the Company's Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 45,000,000 to 90,000,000. |
Management |
For |
For |
| 3. |
FOR the approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers. |
Management |
For |
For |
| 4. |
FOR the |
|
|
|
| ratification of the appointment of KPMG LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2020. |
Management |
For |
For |
|
INTRA-CELLULAR THERAPIES INC
| Security |
46116X101 |
Meeting Type |
Annual |
| Ticker Symbol |
ITCI |
Meeting Date |
27-May-2020 |
| Record Date |
06-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Richard Lerner, M.D. |
For |
For |
| 2. |
To approve an amendment and restatement of the Company's 2018 Equity Incentive Plan. |
Management |
For |
For |
| 3. |
To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 4. |
To approve by an advisory vote the compensation of the Company's named executive officers, as disclosed in the proxy statement. |
Management |
For |
For |
INTUITIVE SURGICAL, INC.
| Security |
46120E602 |
Meeting Type |
Annual |
| Ticker Symbol |
ISRG |
Meeting Date |
23-Apr-2020 |
| Record Date |
28-Feb-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Craig H. Barratt, Ph.D. |
Management |
For |
For |
| 1B. |
Election of Director: Joseph C. Beery |
Management |
For |
For |
| 1C. |
Election of Director: Gary S. Guthart, Ph.D. |
Management |
For |
For |
| 1D. |
Election of Director: Amal M. Johnson |
Management |
For |
For |
| 1E. |
Election of Director: Don R. Kania, Ph.D. |
Management |
For |
For |
| 1F. |
Election of Director: Amy L. Ladd, M.D. |
Management |
For |
For |
| 1G. |
Election of Director: Keith R. Leonard, Jr. |
Management |
For |
For |
| 1H. |
Election of Director: Alan J. Levy, Ph.D. |
Management |
For |
For |
| 1I. |
Election of Director: Jami Dover Nachtsheim |
Management |
For |
For |
| 1J. |
Election of Director: Mark J. Rubash |
Management |
For |
For |
| 2. |
To approve, by advisory vote, the compensation of the Company's Named Executive Officers. |
Management |
For |
For |
| 3. |
The ratification of appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 4. |
To approve the Company's Amended and Restated 2010 Incentive Award Plan. |
Management |
For |
For |
| 5. |
To approve the amendment of the Certificate of Incorporation to adopt simple majority voting provisions. |
Management |
For |
For |
| 6. |
To approve the amendment of the Certificate of Incorporation to permit stockholders to call a special meeting. |
Management |
For |
For |
IO LIGHT HOLDINGS INC.
| Security |
N/A |
Meeting Type |
Written Consent |
| Ticker Symbol |
N/A |
Meeting Date |
29-Apr-2020 |
| Record Date |
N/A |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1 |
Shareholder rights |
Management |
For |
For |
Field: Page; Sequence: 35
Field: /Page
IONIS PHARMACEUTICALS, INC.
| Security |
462222100 |
Meeting Type |
Annual |
| Ticker Symbol |
IONS |
Meeting Date |
04-Jun-2020 |
| Record Date |
06-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Joseph Wender |
For |
For |
|
2 |
B. Lynne Parshall |
For |
For |
|
3 |
Spencer Berthelsen |
For |
For |
|
4 |
Joan Herman |
For |
For |
| 2. |
To approve an amendment and restatement of the Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under such plan by 800,000 shares to an aggregate of 2,800,000 shares, reduce the amount of the automatic awards under the plan, revise the vesting schedule of awards and extend the term of the plan. |
Management |
For |
For |
| 3. |
To ratify amending the existing stock option and restricted stock unit awards of directors to adjust vesting. |
Management |
For |
For |
| 4. |
To approve, by non-binding |
|
|
|
| vote, executive compensation. |
Management |
For |
For |
|
| 5. |
Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2020 fiscal year. |
Management |
For |
For |
IOVANCE BIOTHERAPEUTICS, INC.
| Security |
462260100 |
Meeting Type |
Annual |
| Ticker Symbol |
IOVA |
Meeting Date |
08-Jun-2020 |
| Record Date |
16-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Iain Dukes, D. Phil |
For |
For |
|
2 |
Maria Fardis, PhD, MBA |
For |
For |
|
3 |
Athena Countouriotis MD |
For |
For |
|
4 |
Ryan Maynard |
For |
For |
|
5 |
Merrill A. McPeak |
For |
For |
|
6 |
Wayne P. Rothbaum |
For |
For |
|
7 |
Michael Weiser, MD, PhD |
For |
For |
| 2. |
To approve, by non-binding advisory vote, the compensation of our named executive officers |
Management |
For |
For |
| 3. |
To approve, by non-binding advisory vote, the frequency of future votes on the compensation of our named executive officers |
Management |
For |
For |
| 4. |
To approve an amendment to our 2018 Equity Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder from 6,000,000 shares to 14,000,000 shares |
Management |
For |
For |
| 5. |
To approve our 2020 Employee Stock Purchase Plan |
Management |
For |
For |
| 6. |
To ratify the appointment of Marcum LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2020 |
Management |
For |
For |
IQVIA HOLDINGS INC.
| Security |
46266C105 |
Meeting Type |
Annual |
| Ticker Symbol |
IQV |
Meeting Date |
06-Apr-2020 |
| Record Date |
12-Feb-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Carol J. Burt |
For |
For |
|
2 |
Colleen A. Goggins |
For |
For |
|
3 |
Ronald A. Rittenmeyer |
For |
For |
| 2. |
An advisory (non-binding) vote to approve executive compensation. |
Management |
For |
For |
| 3. |
The ratification of the appointment of PricewaterhouseCoopers LLP as IQVIA Holdings Inc.'s independent registered public accounting firm for the year ending December 31, 2020. |
Management |
For |
For |
JAZZ PHARMACEUTICALS PLC
| Security |
G50871105 |
Meeting Type |
Annual |
| Ticker Symbol |
JAZZ |
Meeting Date |
01-Aug-2019 |
| Record Date |
05-Jun-2019 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1a. |
Election of Director: Paul L. Berns |
Management |
For |
For |
| 1b. |
Election of Director: Patrick G. Enright |
Management |
For |
For |
| 1c. |
Election of Director: Seamus Mulligan |
Management |
For |
For |
| 1d. |
Election of Director: Norbert G. Riedel |
Management |
For |
For |
| 2. |
To ratify, on a non-binding advisory basis, the appointment of KPMG, Dublin as the independent auditors of Jazz Pharmaceuticals plc for the fiscal year ending December 31, 2019 and to authorize, in a binding vote, the board of directors, acting through the audit committee, to determine the auditors' remuneration. |
Management |
For |
For |
| 3. |
To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's named executive officers as disclosed in the proxy statement. |
Management |
For |
For |
Field: Page; Sequence: 36
Field: /Page
JOHNSON & JOHNSON
| Security |
478160104 |
Meeting Type |
Annual |
| Ticker Symbol |
JNJ |
Meeting Date |
23-Apr-2020 |
| Record Date |
25-Feb-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Mary C. Beckerle |
Management |
For |
For |
| 1B. |
Election Of Director: D. Scott Davis |
Management |
For |
For |
| 1C. |
Election of Director: Ian E. L. Davis |
Management |
For |
For |
| 1D. |
Election of Director: Jennifer A. Doudna |
Management |
For |
For |
| 1E. |
Election of Director: Alex Gorsky |
Management |
For |
For |
| 1F. |
Election of Director: Marillyn A. Hewson |
Management |
For |
For |
| 1G. |
Election of Director: Hubert Joly |
Management |
For |
For |
| 1H. |
Election of Director: Mark B. McClellan |
Management |
For |
For |
| 1I. |
Election of Director: Anne M. Mulcahy |
Management |
For |
For |
| 1J. |
Election of Director: Charles Prince |
Management |
For |
For |
| 1K. |
Election of Director: A. Eugene Washington |
Management |
For |
For |
| 1L. |
Election of Director: Mark A. Weinberger |
Management |
For |
For |
| 1M. |
Election of Director: Ronald A. Williams |
Management |
For |
For |
| 2. |
Advisory Vote to Approve Named Executive Officer Compensation. |
Management |
For |
For |
| 3. |
Ratification of Appointment of PricewaterhouseCoopers LLP as the Independent Registered Public Accounting Firm for 2020. |
Management |
For |
For |
| 4. |
Amendment to the Restated Certificate of Incorporation to Permit Removal of Directors Without Cause. |
Management |
For |
For |
| 5. |
Independent Board Chair |
Shareholder |
For |
Against |
| 6. |
Report on Governance of Opioids-Related Risks |
Shareholder |
Against |
For |
KODIAK SCIENCES INC.
| Security |
50015M109 |
Meeting Type |
Annual |
| Ticker Symbol |
KOD |
Meeting Date |
08-Jun-2020 |
| Record Date |
09-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Taiyin Yang, Ph.D. |
For |
For |
|
2 |
Bassil I. Dahiyat, PhD |
For |
For |
|
3 |
Charles Bancroft |
For |
For |
| 2. |
To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2020. |
Management |
For |
For |
LABORATORY CORP. OF AMERICA HOLDINGS
| Security |
50540R409 |
Meeting Type |
Annual |
| Ticker Symbol |
LH |
Meeting Date |
13-May-2020 |
| Record Date |
25-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Kerrii B. Anderson |
Management |
For |
For |
| 1B. |
Election of Director: Jean-Luc Bélingard |
Management |
For |
For |
| 1C. |
Election of Director: Jeffrey A. Davis |
Management |
For |
For |
| 1D. |
Election of Director: D. Gary Gilliland, M.D., Ph.D. |
Management |
For |
For |
| 1E. |
Election of Director: Garheng Kong, M.D., Ph.D. |
Management |
For |
For |
| 1F. |
Election of Director: Peter M. Neupert |
Management |
For |
For |
| 1G. |
Election of Director: Richelle P. Parham |
Management |
For |
For |
| 1H. |
Election of Director: Adam H. Schechter |
Management |
For |
For |
| 1I. |
Election of Director: R. Sanders Williams, M.D. |
Management |
For |
For |
| 2. |
To approve, by non-binding vote, executive compensation. |
Management |
For |
For |
| 3. |
Ratification of the appointment of PricewaterhouseCoopers LLP as Laboratory Corporation of America Holdings' independent registered public accounting firm for 2020. |
Management |
For |
For |
| 4. |
Shareholder proposal seeking the power for shareholders of 10% or more of our common stock to call a special shareholder meeting. |
Shareholder |
Against |
For |
Field: Page; Sequence: 37
Field: /Page
LIGAND PHARMACEUTICALS INCORPORATED
| Security |
53220K504 |
Meeting Type |
Annual |
| Ticker Symbol |
LGND |
Meeting Date |
10-Jun-2020 |
| Record Date |
14-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Jason M. Aryeh |
For |
For |
|
2 |
Sarah Boyce |
For |
For |
|
3 |
Todd C. Davis |
For |
For |
|
4 |
Nancy R. Gray, Ph.D. |
For |
For |
|
5 |
John L. Higgins |
For |
For |
|
6 |
John W. Kozarich, Ph.D. |
For |
For |
|
7 |
John L. LaMattina, Ph.D |
For |
For |
|
8 |
Sunil Patel |
For |
For |
|
9 |
Stephen L. Sabba, M.D. |
For |
For |
| 2. |
Ratification of Ernst & Young LLP as Ligand's Independent Registered Public Accounting Firm. |
Management |
For |
For |
| 3. |
Approval, on an advisory basis, of the Compensation of the Named Executive Officers. |
Management |
For |
For |
MADRIGAL PHARMACEUTICALS INC.
| Security |
558868105 |
Meeting Type |
Annual |
| Ticker Symbol |
MDGL |
Meeting Date |
17-Jun-2020 |
| Record Date |
24-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Paul A. Friedman, M.D. |
For |
For |
|
2 |
Kenneth M. Bate |
For |
For |
|
3 |
James M. Daly |
For |
For |
| 2. |
To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 3. |
Advisory vote on compensation of named executive officers. |
Management |
For |
For |
| 4. |
In their discretion, the proxies are authorized to vote and act upon any other matters which may properly come before the meeting or any adjournment or postponement thereof. |
Management |
For |
For |
MCKESSON CORPORATION
| Security |
58155Q103 |
Meeting Type |
Annual |
| Ticker Symbol |
MCK |
Meeting Date |
31-Jul-2019 |
| Record Date |
04-Jun-2019 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1a. |
Election of Director for a one-year term: Dominic J. Caruso |
Management |
For |
For |
| 1b. |
Election of Director for a one-year term: N. Anthony Coles, M.D. |
Management |
For |
For |
| 1c. |
Election of Director for a one-year term: M. Christine Jacobs |
Management |
For |
For |
| 1d. |
Election of Director for a one-year term: Donald R. Knauss |
Management |
For |
For |
| 1e. |
Election of Director for a one-year term: Marie L. Knowles |
Management |
For |
For |
| 1f. |
Election of Director for a one-year term: Bradley E. Lerman |
Management |
For |
For |
| 1g. |
Election of Director for a one-year term: Edward A. Mueller |
Management |
For |
For |
| 1h. |
Election of Director for a one-year term: Susan R. Salka |
Management |
For |
For |
| 1i. |
Election of Director for a one-year term: Brian S. Tyler |
Management |
For |
For |
| 1j. |
Election of Director for a one-year term: Kenneth E. Washington |
Management |
For |
For |
| 2. |
Ratification of the appointment of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending March 31, 2020. |
Management |
For |
For |
| 3. |
Advisory vote on executive compensation. |
Management |
For |
For |
| 4. |
Shareholder proposal on disclosure of lobbying activities and expenditures. |
Shareholder |
Against |
For |
| 5. |
Shareholder proposal on 10% ownership threshold for calling special meetings of shareholders. |
Shareholder |
Against |
For |
Field: Page; Sequence: 38
Field: /Page
MEDPACE HOLDINGS, INC.
| Security |
58506Q109 |
Meeting Type |
Annual |
| Ticker Symbol |
MEDP |
Meeting Date |
15-May-2020 |
| Record Date |
20-Mar-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Brian T. Carley |
For |
For |
|
2 |
Thomas C. King |
For |
For |
|
3 |
Robert O. Kraft |
For |
For |
| 2. |
To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending December 31, 2020. |
Management |
For |
For |
| 3. |
To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement for the 2020 Annual Meeting. |
Management |
For |
For |
| 4. |
To recommend, on an advisory basis, the frequency of the advisory vote on named executive officer compensation. |
Management |
1 Year |
For |
MEDTRONIC PLC
| Security |
G5960L103 |
Meeting Type |
Annual |
| Ticker Symbol |
MDT |
Meeting Date |
06-Dec-2019 |
| Record Date |
10-Oct-2019 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Richard H. Anderson |
Management |
For |
For |
| 1B. |
Election of Director: Craig Arnold |
Management |
For |
For |
| 1C. |
Election of Director: Scott C. Donnelly |
Management |
For |
For |
| 1D. |
Election of Director: Andrea J. Goldsmith, Ph.D. |
Management |
For |
For |
| 1E. |
Election of Director: Randall J. Hogan, III |
Management |
For |
For |
| 1F. |
Election of Director: Omar Ishrak |
Management |
For |
For |
| 1G. |
Election of Director: Michael O. Leavitt |
Management |
For |
For |
| 1H. |
Election of Director: James T. Lenehan |
Management |
For |
For |
| 1I. |
Election of Director: Geoffrey S. Martha |
Management |
For |
For |
| 1J. |
Election of Director: Elizabeth G. Nabel, M.D. |
Management |
For |
For |
| 1K. |
Election of Director: Denise M. O'Leary |
Management |
For |
For |
| 1L. |
Election of Director: Kendall J. Powell |
Management |
For |
For |
| 2. |
To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as Medtronic's independent auditor for fiscal year 2020 and to authorize, in a binding vote, the Board of Directors, acting through the Audit Committee, to set the auditor's remuneration. |
Management |
For |
For |
| 3. |
To approve, in a non-binding advisory vote, named executive officer compensation (a "Say-on-Pay" vote). |
Management |
For |
For |
| 4. |
To renew the Board's authority to issue shares. |
Management |
For |
For |
| 5. |
To renew the Board's authority to opt out of pre-emption rights. |
Management |
For |
For |
| 6. |
Authorizing the Company and any subsidiary of the Company to make overseas market purchases of Medtronic ordinary shares. |
Management |
For |
For |
MERCK & CO., INC.
| Security |
58933Y105 |
Meeting Type |
Annual |
| Ticker Symbol |
MRK |
Meeting Date |
26-May-2020 |
| Record Date |
27-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Leslie A. Brun |
Management |
For |
For |
| 1B. |
Election of Director: Thomas R. Cech |
Management |
For |
For |
| 1C. |
Election of Director: Mary Ellen Coe |
Management |
For |
For |
| 1D. |
Election of Director: Pamela J. Craig |
Management |
For |
For |
| 1E. |
Election of Director: Kenneth C. Frazier |
Management |
For |
For |
| 1F. |
Election of Director: Thomas H. Glocer |
Management |
For |
For |
| 1G. |
Election of Director: Risa Lavizzo-Mourey |
Management |
For |
For |
| 1H. |
Election of Director: Paul B. Rothman |
Management |
For |
For |
| 1I. |
Election of Director: Patricia F. Russo |
Management |
For |
For |
| 1J. |
Election of Director: Christine E. Seidman |
Management |
For |
For |
| 1K. |
Election of Director: Inge G. Thulin |
Management |
For |
For |
| 1L. |
Election of Director: Kathy J. Warden |
Management |
For |
For |
| 1M. |
Election of Director: Peter C. Wendell |
Management |
For |
For |
| 2. |
Non-binding advisory vote to approve the compensation of our named executive officers. |
Management |
For |
For |
| 3. |
Ratification of the appointment of the Company's independent registered public accounting firm for 2020. |
Management |
For |
For |
| 4. |
Shareholder proposal concerning shareholder right to act by written consent. |
Shareholder |
Against |
For |
| 5. |
Shareholder proposal regarding allocation of corporate tax savings. |
Shareholder |
Against |
For |
Field: Page; Sequence: 39
Field: /Page
Field: Split-Segment; Name: 4
MILESTONE PHARMACEUTICALS INC.
| Security |
59935V107 |
Meeting Type |
Annual |
| Ticker Symbol |
MIST |
Meeting Date |
05-Jun-2020 |
| Record Date |
07-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1 |
DIRECTOR |
Management |
|
|
|
1 |
Joseph Oliveto |
For |
For |
|
2 |
Paul Edick |
For |
For |
|
3 |
Richard Pasternak |
For |
For |
|
4 |
Debra K. Liebert |
For |
For |
|
5 |
Michael Tomsicek |
For |
For |
|
6 |
Paul Truex |
For |
For |
| 2 |
Appointment of PricewaterhouseCoopers LLP as auditors for the Company to hold office until the close of the 2021 Annual Meeting of Shareholders and the Board of Directors of the Company is hereby authorized to fix the auditors' remuneration. |
Management |
For |
For |
MIRATI THERAPEUTICS, INC.
| Security |
60468T105 |
Meeting Type |
Annual |
| Ticker Symbol |
MRTX |
Meeting Date |
12-May-2020 |
| Record Date |
19-Mar-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Charles M. Baum |
For |
For |
|
2 |
Bruce L.A. Carter |
For |
For |
|
3 |
Julie M. Cherrington |
For |
For |
|
4 |
Aaron I. Davis |
For |
For |
|
5 |
Henry J. Fuchs |
For |
For |
|
6 |
Michael Grey |
For |
For |
|
7 |
Faheem Hasnain |
For |
For |
|
8 |
Craig Johnson |
For |
For |
|
9 |
Maya Martinez-Davis |
For |
For |
| 2. |
To approve, on an advisory basis, the compensation paid to our named executive officers as disclosed in the proxy statement. |
Management |
For |
For |
| 3. |
To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2020. |
Management |
For |
For |
Field: Page; Sequence: 40
Field: /Page
MODERNA, INC.
| Security |
60770K107 |
Meeting Type |
Annual |
| Ticker Symbol |
MRNA |
Meeting Date |
29-Apr-2020 |
| Record Date |
02-Mar-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Stephen Berenson |
For |
For |
|
2 |
Sandra Horning, MD |
For |
For |
|
3 |
Paul Sagan |
For |
For |
| 2. |
To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2020. |
Management |
For |
For |
| 3. |
To cast a non-binding, advisory vote to approve the compensation of our named executive officers. |
Management |
For |
For |
| 4. |
To cast a non-binding, advisory vote on the frequency of future non-binding, advisory votes to approve the compensation of our named executive officers every. |
Management |
2 Years |
Against |
MOLECULAR TEMPLATES, INC.
| Security |
608550109 |
Meeting Type |
Annual |
| Ticker Symbol |
MTEM |
Meeting Date |
28-May-2020 |
| Record Date |
08-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1.1 |
Election of Director: Eric E. Poma, Ph.D. |
Management |
For |
For |
| 1.2 |
Election of Director: Harold E. Selick, Ph.D. |
Management |
For |
For |
| 2. |
Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 3. |
Approve on an advisory basis the compensation of the Company's named executive officers, as disclosed pursuant to the compensation disclosure rules of the Securities and Exchange Commission. |
Management |
For |
For |
MOMENTA PHARMACEUTICALS, INC.
| Security |
60877T100 |
Meeting Type |
Annual |
| Ticker Symbol |
MNTA |
Meeting Date |
23-Jun-2020 |
| Record Date |
27-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Class I Director: Bruce L. Downey |
Management |
For |
For |
| 1B. |
Election of Class I Director: Georges Gemayel |
Management |
For |
For |
| 2. |
To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020 |
Management |
For |
For |
| 3. |
To approve, on an advisory (non-binding) basis, the compensation of our named executive officers |
Management |
For |
For |
| 4. |
To approve the amendment and restatement of the Momenta Pharmaceuticals, Inc. 2013 Incentive Award Plan, which, among other things, increases the number of shares authorized for issuance by 7,000,000 shares. |
Management |
For |
For |
Field: Page; Sequence: 41
Field: /Page
MYLAN N.V.
| Security |
N59465109 |
Meeting Type |
Special |
| Ticker Symbol |
MYL |
Meeting Date |
15-Jun-2020 |
| Record Date |
05-Feb-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
Approval of the Combination Proposal: (A) Approval of the Mylan Merger; (B) Approval of the Share Sale; (C) Approval of the Mylan Newco Liquidation; (D) Approval of the Alternative Transaction Structure; and (E) Approval of the Discharge of Directors (in each case with the foregoing capitalized terms as defined in the accompanying proxy statement). |
Management |
For |
For |
| 2. |
Adoption of a non-binding, advisory resolution to adopt the compensation that will or may be paid or become payable to Mylan's named executive officers in connection with, or following, the consummation of the Combination as described in the proxy statement. |
Management |
For |
For |
| 3. |
Adoption of a non-binding, advisory resolution to adopt certain features of Newco's governance which will replace the corresponding features of Mylan's governance, effective upon the closing of the Combination, relating to (i) the right of stockholders to nominate directors and make other stockholder proposals at stockholder meetings and (ii) director terms and stockholder removal of directors. |
Management |
For |
For |
| 4. |
Adoption of a non-binding, advisory resolution to adopt certain features of Newco's governance which will replace the corresponding features of Mylan's governance, effective upon the closing of the Combination, relating to the right of stockholders to call special meetings of stockholders. |
Management |
For |
For |
Field: Page; Sequence: 42
Field: /Page
MYLAN N.V.
| Security |
N59465109 |
Meeting Type |
Special |
| Ticker Symbol |
MYL |
Meeting Date |
30-Jun-2020 |
| Record Date |
02-Jun-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Appointment of the Director: Heather Bresch |
Management |
For |
For |
| 1B. |
Appointment of the Director: Hon. Robert J. Cindrich |
Management |
For |
For |
| 1C. |
Appointment of the Director: Robert J. Coury |
Management |
For |
For |
| 1D. |
Appointment of the Director: JoEllen Lyons Dillon |
Management |
For |
For |
| 1E. |
Appointment of the Director: Neil Dimick, C.P.A. |
Management |
For |
For |
| 1F. |
Appointment of the Director: Melina Higgins |
Management |
For |
For |
| 1G. |
Appointment of the Director: Harry A. Korman |
Management |
For |
For |
| 1H. |
Appointment of the Director: Rajiv Malik |
Management |
For |
For |
| 1I. |
Appointment of the Director: Richard Mark, C.P.A. |
Management |
For |
For |
| 1J. |
Appointment of the Director: Mark W. Parrish |
Management |
For |
For |
| 1K. |
Appointment of the Director: Pauline van der Meer Mohr |
Management |
For |
For |
| 1L. |
Appointment of the Director: Randall L. (Pete) Vanderveen, Ph.D. |
Management |
For |
For |
| 1M. |
Appointment of the Director: Sjoerd S. Vollebregt |
Management |
For |
For |
| 2. |
Approval, on an advisory basis, of the compensation of the named executive officers of the Company. |
Management |
For |
For |
| 3. |
Adoption of the Dutch annual accounts for fiscal year 2019. |
Management |
For |
For |
| 4. |
Ratification of the selection of Deloitte & Touche LLP as Mylan's independent registered public accounting firm for fiscal year 2020. |
Management |
For |
For |
| 5. |
Instruction to Deloitte Accountants B.V. for the audit of Mylan's Dutch statutory annual accounts for fiscal year 2020. |
Management |
For |
For |
| 6. |
Authorization of the Board to acquire shares in the capital of the Company. |
Management |
For |
For |
| 7. |
Delegation to the Board of the authority to issue ordinary shares and grant rights to subscribe for ordinary shares in the capital of the Company and to exclude or restrict pre-emptive rights. |
Management |
For |
For |
| E1E |
Approval of the |
|
|
|
| Combination Proposal. ...(due to space limits, see proxy material for full proposal). |
Management |
For |
For |
|
| E2E |
Adoption of a non-binding, advisory resolution to adopt the compensation that will or may be paid or become payable to Mylan's named executive officers in connection with, or following, the consummation of the Combination as described in the proxy statement. |
Management |
For |
For |
| E3E |
Adoption of a non-binding, advisory resolution to adopt certain features of Newco's governance which will replace the corresponding features of Mylan's governance, effective upon the closing of the Combination, relating to (i) the right of stockholders to nominate directors and make other stockholder proposals at stockholder meetings and (ii) director terms and stockholder removal of directors. |
Management |
For |
For |
| E4E |
Adoption of a non-binding, advisory resolution to adopt certain features of Newco's governance which will replace the corresponding features of Mylan's governance, effective upon the closing of the Combination, relating to the right of stockholders to call special meetings of stockholders. |
Management |
For |
For |
Field: Page; Sequence: 43
Field: /Page
MYOKARDIA, INC.
| Security |
62857M105 |
Meeting Type |
Annual |
| Ticker Symbol |
MYOK |
Meeting Date |
18-Jun-2020 |
| Record Date |
20-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
David P. Meeker, M.D. |
For |
For |
|
2 |
Mark L. Perry |
For |
For |
|
3 |
Wendy L. Yarno |
For |
For |
| 2. |
To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020. |
Management |
For |
For |
| 3. |
To recommend, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement. |
Management |
For |
For |
NEKTAR THERAPEUTICS
| Security |
640268108 |
Meeting Type |
Annual |
| Ticker Symbol |
NKTR |
Meeting Date |
17-Jun-2020 |
| Record Date |
20-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Karin Eastham |
Management |
For |
For |
| 1B. |
Election of Director: Myriam J. Curet |
Management |
For |
For |
| 1C. |
Election of Director: Howard W. Robin |
Management |
For |
For |
| 2. |
To approve an amendment of our Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under the plan by 10,000,000 shares. |
Management |
For |
For |
| 3. |
To approve an amendment and restatement of our Amended and Restated Employee Stock Purchase Plan to increase the aggregate number of shares of common stock authorized under the plan by 1,000,000 shares. |
Management |
For |
For |
| 4. |
To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 5. |
To approve a non-binding advisory resolution regarding our executive compensation (a "say-on-pay" vote). |
Management |
For |
For |
Field: Page; Sequence: 44
Field: /Page
NEUROCRINE BIOSCIENCES, INC.
| Security |
64125C109 |
Meeting Type |
Annual |
| Ticker Symbol |
NBIX |
Meeting Date |
19-May-2020 |
| Record Date |
23-Mar-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Kevin C. Gorman, Ph.D. |
For |
For |
|
2 |
Gary A. Lyons |
For |
For |
| 2. |
Advisory vote to approve the compensation paid to the Company's named executive officers. |
Management |
For |
For |
| 3. |
To approve the Company's 2020 Equity Incentive Plan. |
Management |
For |
For |
| 4. |
To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
NOVOCURE LIMITED
| Security |
G6674U108 |
Meeting Type |
Annual |
| Ticker Symbol |
NVCR |
Meeting Date |
10-Jun-2020 |
| ISIN |
JE00BYSS4X48 |
Agenda |
935188602 - Management |
| Record Date |
03-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Jeryl Hilleman |
Management |
For |
For |
| 1B. |
Election of Director: David Hung |
Management |
For |
For |
| 1C. |
Election of Director: Kinyip Gabriel Leung |
Management |
For |
For |
| 1D. |
Election of Director: Martin Madden |
Management |
For |
For |
| 1E. |
Election of Director: Sherilyn McCoy |
Management |
For |
For |
| 2. |
The approval and ratification of the appointment, by the Audit Committee of our Board of Directors, of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the auditor and independent registered public accounting firm of the Company for the Company's fiscal year ending December 31, 2020. |
Management |
For |
For |
| 3. |
A non-binding advisory vote to approve executive compensation. |
Management |
For |
For |
Field: Page; Sequence: 45
Field: /Page
OCULIS SA
| Security |
N/A |
Meeting Type |
Extraordinary General Meeting |
| Ticker Symbol |
N/A |
Meeting Date |
26-Nov-2019 |
| Record Date |
N/A |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1 |
Ordinary Share Capital Increase |
Management |
For |
For |
| 2 |
Conditional Share Capital Increase |
Management |
For |
For |
OCULIS SA
| Security |
N/A |
Meeting Type |
Written Consent |
| Ticker Symbol |
N/A |
Meeting Date |
9-Mar-2020 |
| Record Date |
N/A |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
Ordinary Share Capital Increase |
Management |
For |
For |
| 2. |
Conditional Share Capital Increase |
Management |
For |
For |
OCULIS SA
| Security |
N/A |
Meeting Type |
Annual General Meeting |
| Ticker Symbol |
N/A |
Meeting Date |
25-Jun-2020 |
| Record Date |
N/A |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
Approval of Annual Report including Financial Statements |
Management |
For |
For |
| 2. |
Appropriation of Balance Sheet Result 2019 |
Management |
For |
For |
| 3. |
Discharge of the Members of the Board and Management |
Management |
For |
For |
| 4. |
Re-Election of Board of Directors |
Management |
For |
For |
| 5. |
Re-Election of the Auditors |
Management |
For |
For |
Field: Page; Sequence: 46
Field: /Page
OVID THERAPEUTICS INC.
| Security |
690469101 |
Meeting Type |
Annual |
| Ticker Symbol |
OVID |
Meeting Date |
04-Jun-2020 |
| Record Date |
09-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Class III director to hold office until the 2023 Annual Meeting of Stockholders: Jeremy M. Levin |
Management |
For |
For |
| 1B. |
Election of Class III director to hold office until the 2023 Annual Meeting of Stockholders: Karen Bernstein |
Management |
For |
For |
| 2. |
Ratification of the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
PERKINELMER, INC.
| Security |
714046109 |
Meeting Type |
Annual |
| Ticker Symbol |
PKI |
Meeting Date |
28-Apr-2020 |
| Record Date |
28-Feb-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Peter Barrett |
Management |
For |
For |
| 1B. |
Election of Director: Samuel R. Chapin |
Management |
For |
For |
| 1C. |
Election of Director: Sylvie Grégoire, PharmD |
Management |
For |
For |
| 1D. |
Election of Director: Alexis P. Michas |
Management |
For |
For |
| 1E. |
Election of Director: Prahlad R. Singh, PhD |
Management |
For |
For |
| 1F. |
Election of Director: Michel Vounatsos |
Management |
For |
For |
| 1G. |
Election of Director: Frank Witney, PhD |
Management |
For |
For |
| 1H. |
Election of Director: Pascale Witz |
Management |
For |
For |
| 2. |
To ratify the selection of Deloitte & Touche LLP as PerkinElmer's independent registered public accounting firm for the current fiscal year. |
Management |
For |
For |
| 3. |
To approve, by non-binding advisory vote, our executive compensation. |
Management |
For |
For |
PFIZER INC.
| Security |
717081103 |
Meeting Type |
Annual |
| Ticker Symbol |
PFE |
Meeting Date |
23-Apr-2020 |
| Record Date |
25-Feb-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Ronald E. Blaylock |
Management |
For |
For |
| 1B. |
Election of Director: Albert Bourla |
Management |
For |
For |
| 1C. |
Election of Director: W. Don Cornwell |
Management |
For |
For |
| 1D. |
Election of Director: Joseph J. Echevarria |
Management |
For |
For |
| 1E. |
Election of Director: Scott Gottlieb |
Management |
For |
For |
| 1F. |
Election of Director: Helen H. Hobbs |
Management |
For |
For |
| 1G. |
Election of Director: Susan Hockfield |
Management |
For |
For |
| 1H. |
Election of Director: James M. Kilts |
Management |
For |
For |
| 1I. |
Election of Director: Dan R. Littman |
Management |
For |
For |
| 1J. |
Election of Director: Shantanu Narayen |
Management |
For |
For |
| 1K. |
Election of Director: Suzanne Nora Johnson |
Management |
For |
For |
| 1L. |
Election of Director: James Quincey |
Management |
For |
For |
| 1M. |
Election of Director: James C. Smith |
Management |
For |
For |
| 2. |
Ratify the selection of KPMG LLP as independent registered public accounting firm for 2020 |
Management |
For |
For |
| 3. |
2020 advisory approval of executive compensation |
Management |
For |
For |
| 4. |
Shareholder proposal regarding right to act by written consent |
Shareholder |
Against |
For |
| 5. |
Shareholder proposal regarding enhancing proxy access |
Shareholder |
Against |
For |
| 6. |
Shareholder proposal regarding report on lobbying activities |
Shareholder |
Against |
For |
| 7. |
Shareholder proposal regarding independent chair policy |
Shareholder |
For |
Against |
| 8. |
Shareholder proposal regarding gender pay gap |
Shareholder |
Against |
For |
| 9. |
Election of Director: Susan Desmond-Hellmann |
Management |
For |
For |
Field: Page; Sequence: 47
Field: /Page
PIERIS PHARMACEUTICALS, INC.
| Security |
720795103 |
Meeting Type |
Annual |
| Ticker Symbol |
PIRS |
Meeting Date |
31-Jul-2019 |
| Record Date |
03-Jun-2019 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
James Geraghty |
For |
For |
|
2 |
Ann Barbier, M.D.,Ph.D. |
For |
For |
| 2. |
Approve the Company's 2019 Employee, Director and Consultant Equity Incentive Plan. |
Management |
For |
For |
| 3. |
Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2019. |
Management |
For |
For |
PIERIS PHARMACEUTICALS, INC.
| Security |
720795103 |
Meeting Type |
Annual |
| Ticker Symbol |
PIRS |
Meeting Date |
23-Jun-2020 |
| Record Date |
24-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Stephen S. Yoder |
For |
For |
|
2 |
Michael Richman |
For |
For |
|
3 |
Matthew L. Sherman, M.D |
For |
For |
| 2. |
Approve the Company's 2020 Employee, Director and Consultant Equity Incentive Plan. |
Management |
For |
For |
| 3. |
Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 4 |
Approve, on non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in this proxy statement. |
Management |
For |
For |
| 5. |
The preferred frequency for future non-binding advisory votes to approve the compensation of the Company's named executive officers. |
Management |
1 Year |
For |
PORTOLA PHARMACEUTICALS, INC.
| Security |
737010108 |
Meeting Type |
Annual |
| Ticker Symbol |
PTLA |
Meeting Date |
12-Jun-2020 |
| Record Date |
17-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Jeffrey Bird, M.D., PhD |
For |
For |
|
2 |
John H. Johnson |
For |
For |
|
3 |
H. Ward Wolff |
For |
For |
| 2. |
To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in this proxy statement. |
Management |
For |
For |
| 3. |
To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
Field: Page; Sequence: 48
Field: /Page
PRA HEALTH SCIENCES, INC.
| Security |
69354M108 |
Meeting Type |
Annual |
| Ticker Symbol |
PRAH |
Meeting Date |
18-May-2020 |
| Record Date |
20-Mar-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Colin Shannon |
For |
For |
|
2 |
James C. Momtazee |
For |
For |
|
3 |
Alexander G. Dickinson |
For |
For |
| 2. |
To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for 2020. |
Management |
For |
For |
| 3. |
Approval, in a non-binding advisory vote, of the compensation paid to the Company's named executive officers. |
Management |
For |
For |
| 4. |
Approval of the PRA Health Sciences, Inc. 2020 Stock Incentive Plan. |
Management |
For |
For |
PTC THERAPEUTICS, INC.
| Security |
69366J200 |
Meeting Type |
Annual |
| Ticker Symbol |
PTCT |
Meeting Date |
10-Jun-2020 |
| Record Date |
17-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1 |
DIRECTOR |
Management |
|
|
|
1 |
Stephanie S. Okey, M.S. |
For |
For |
|
2 |
Stuart W. Peltz, Ph.D. |
For |
For |
|
3 |
Jerome B. Zeldis, M.D. |
For |
For |
| 2 |
Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 3 |
Advisory vote to approve named executive officer compensation. |
Management |
For |
For |
PUMA BIOTECHNOLOGY, INC.
| Security |
74587V107 |
Meeting Type |
Annual |
| Ticker Symbol |
PBYI |
Meeting Date |
09-Jun-2020 |
| Record Date |
15-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Alan H. Auerbach |
For |
For |
|
2 |
Ann C. Miller |
For |
For |
|
3 |
Michael P. Miller |
For |
For |
|
4 |
Jay M. Moyes |
For |
For |
|
5 |
Hugh O'Dowd |
For |
For |
|
6 |
Adrian M. Senderowicz |
For |
For |
|
7 |
Troy E. Wilson |
For |
For |
|
8 |
Frank E. Zavrl |
For |
For |
| 2. |
Ratification of the selection of KPMG LLP as independent registered public accounting firm of Puma Biotechnology, Inc. for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 3. |
Advisory (non-binding) vote to approve the compensation of Puma Biotechnology, Inc.'s named executive officers as described in the proxy statement. |
Management |
For |
For |
Field: Page; Sequence: 49
Field: /Page
QUOTIENT LIMITED
| Security |
G73268107 |
Meeting Type |
Annual |
| Ticker Symbol |
QTNT |
Meeting Date |
30-Oct-2019 |
| Record Date |
28-Aug-2019 |
|
|
| Item |
Proposal |
|
Proposed by |
Vote |
For/Against Management |
| 1. |
DIRECTOR |
|
Management |
|
|
|
1 |
Franz Walt |
|
For |
For |
|
2 |
Thomas Bologna |
|
For |
For |
|
3 |
Frederick Hallsworth |
|
For |
For |
|
4 |
Brian McDonough |
|
For |
For |
|
5 |
Sarah O'Connor |
|
For |
For |
|
6 |
Heino von Prondzynski |
|
For |
For |
|
7 |
Zubeen Shroff |
|
For |
For |
|
8 |
John Wilkerson |
|
For |
For |
|
9 |
Proposal to re-appoint Ernst & Young LLP as our |
|
|
|
| auditors to hold office from the conclusion of this meeting until the conclusion of the Annual Meeting of the Company to be held |
|
|
|
|
|
| in 2020, that the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for purposes |
|
|
|
|
|
| of United States securities law reporting for the fiscal year ending March 31, 2020 be ratified and that the directors be authorized. |
Management |
For |
For |
|
|
RAINIER THERAPEUTICS, INC.
| Security |
N/A |
Meeting Type |
Written Consent |
| Ticker Symbol |
N/A |
Meeting Date |
11-Jul-2019 |
| Record Date |
N/A |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
Authorization and Approval of Unsecured Note Amendment and Secured Note Financing |
Management |
For |
For |
| 2. |
Security Interest Grant to Note Recipients |
Management |
For |
For |
| 3. |
General Authorizing Resolution |
Management |
For |
For |
RAINIER THERAPEUTICS, INC.
| Security |
N/A |
Meeting Type |
Written Consent |
| Ticker Symbol |
N/A |
Meeting Date |
30-Oct-2019 |
| Record Date |
N/A |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
Adoption of Change in Control Retention Plan |
Management |
For |
For |
| 2. |
General Authorizing Resolution |
Management |
For |
For |
Field: Page; Sequence: 50
Field: /Page
RAINIER THERAPEUTICS, INC.
| Security |
N/A |
Meeting Type |
Written Consent |
| Ticker Symbol |
N/A |
Meeting Date |
3-Mar-2020 |
| Record Date |
N/A |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
Asset Purchase Agreement |
Management |
For |
For |
| 2 . |
Appointment of Seller's Representative |
Management |
For |
For |
| 3 . |
Waiver of Notice Requirement |
Management |
For |
For |
| 4 . |
Series A and Series B Stockholder Waiver |
Management |
For |
For |
| 5 . |
Interested Party Transactions |
Management |
For |
For |
| 6 . |
General Authorizing Resolution |
Management |
For |
For |
RAINIER THERAPEUTICS, INC.
| Security |
N/A |
Meeting Type |
Written Consent |
| Ticker Symbol |
N/A |
Meeting Date |
19-May-2020 |
| Record Date |
N/A |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
Adoption of Plan of Complete Liquidation, Liquidation and Dissolution |
Management |
For |
For |
| 2 . |
Interested Party Transactions |
Management |
For |
For |
| 3 . |
Waiver of Notice Requirement |
Management |
For |
For |
RA PHARMACEUTICALS, INC.
| Security |
74933V108 |
Meeting Type |
Special |
| Ticker Symbol |
RARX |
Meeting Date |
17-Dec-2019 |
| Record Date |
12-Nov-2019 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
The proposal to adopt the Merger Agreement. |
Management |
For |
For |
| 2. |
The proposal to approve the adjournment of the Special Meeting to a later date or dates if necessary to solicit additional proxies if there are insufficient votes to approve the proposal to adopt the Merger Agreement at the time of the Special Meeting. |
Management |
For |
For |
RALLYBIO HOLDINGS, LLC
| Security |
N/A |
Meeting Type |
Written Consent |
| Ticker Symbol |
N/A |
Meeting Date |
14-May-2020 |
| Record Date |
N/A |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
Series B Expansion |
Management |
For |
For |
Field: Page; Sequence: 51
Field: /Page
REATA PHARMACEUTICALS, INC.
| Security |
75615P103 |
Meeting Type |
Annual |
| Ticker Symbol |
RETA |
Meeting Date |
10-Jun-2020 |
| Record Date |
16-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
James E. Bass |
For |
For |
|
2 |
R. Kent McGaughy, Jr. |
For |
For |
| 2. |
To approve, on an advisory basis, the compensation of our named executive officers. |
Management |
For |
For |
| 3. |
To approve, on an advisory basis, the frequency of future advisory votes to approve the compensation of our named executive officers. |
Management |
1 Year |
For |
| 4. |
To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
REGENERON PHARMACEUTICALS, INC.
| Security |
75886F107 |
Meeting Type |
Annual |
| Ticker Symbol |
REGN |
Meeting Date |
12-Jun-2020 |
| Record Date |
14-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: N. Anthony Coles, M.D. |
Management |
For |
For |
| 1B. |
Election of Director: Joseph L. Goldstein, M.D. |
Management |
For |
For |
| 1C. |
Election of Director: Christine A. Poon |
Management |
For |
For |
| 1D. |
Election of Director: P. Roy Vagelos, M.D. |
Management |
For |
For |
| 1E. |
Election of Director: Huda Y. Zoghbi, M.D. |
Management |
For |
For |
| 2. |
Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 3. |
Proposal to approve the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. |
Management |
For |
For |
| 4. |
Proposal to approve, on an advisory basis, executive compensation. |
Management |
For |
For |
Field: Page; Sequence: 52
Field: /Page
RESMED INC.
| Security |
761152107 |
Meeting Type |
Annual |
| Ticker Symbol |
RMD |
Meeting Date |
21-Nov-2019 |
| Record Date |
26-Sep-2019 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Carol Burt |
Management |
For |
For |
| 1B. |
Election of Director: Jan De Witte |
Management |
For |
For |
| 1C. |
Election of Director: Richard Sulpizio |
Management |
For |
For |
| 2. |
Ratify our appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2020. |
Management |
For |
For |
| 3. |
Approve, on an advisory basis, the compensation paid to our named executive officers, as disclosed in the proxy statement ("say-on-pay"). |
Management |
For |
For |
REVANCE THERAPEUTICS, INC.
| Security |
761330109 |
Meeting Type |
Annual |
| Ticker Symbol |
RVNC |
Meeting Date |
14-May-2020 |
| Record Date |
16-Mar-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Jill Beraud |
For |
For |
|
2 |
Robert Byrnes |
For |
For |
| 2. |
Ratification of the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 3. |
Approval of, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement. |
Management |
For |
For |
Field: Page; Sequence: 53
Field: /Page
ROCKET PHARMACEUTICALS, INC.
| Security |
77313F106 |
Meeting Type |
Annual |
| Ticker Symbol |
RCKT |
Meeting Date |
16-Jun-2020 |
| Record Date |
20-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Roderick Wong |
Management |
For |
For |
| 1B. |
Election of Director: Carsten Boess |
Management |
For |
For |
| 1C. |
Election of Director: Pedro Granadillo |
Management |
For |
For |
| 1D. |
Election of Director: Gotham Makker |
Management |
For |
For |
| 1E. |
Election of Director: Gaurav Shah |
Management |
For |
For |
| 1F. |
Election of Director: David P. Southwell |
Management |
For |
For |
| 1G. |
Election of Director: Naveen Yalamanchi |
Management |
For |
For |
| 1H. |
Election of Director: Elisabeth Björk |
Management |
For |
For |
| 2. |
Ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 3. |
Stockholder proposal to amend the Company's articles of incorporation and/or by-laws to provide that directors shall be elected by the affirmative vote of the majority of votes cast at an annual meeting of stockholders in uncontested elections. |
Shareholder |
Against |
For |
RUBIUS THERAPEUTICS, INC.
| Security |
78116T103 |
Meeting Type |
Annual |
| Ticker Symbol |
RUBY |
Meeting Date |
21-May-2020 |
| Record Date |
24-Mar-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Noubar B. Afeyan |
For |
For |
|
2 |
Michael Rosenblatt |
For |
For |
|
3 |
Catherine A. Sohn |
For |
For |
| 2. |
To |
|
|
|
| ratify the appointment of PricewaterhouseCoopers LLP as Rubius |
|
|
|
|
| Therapeutics, Inc.'s independent registered public accounting firm for |
|
|
|
|
| the fiscal year ending December 31, 2020. |
Management |
For |
For |
|
SAGE THERAPEUTICS, INC.
| Security |
78667J108 |
Meeting Type |
Annual |
| Ticker Symbol |
SAGE |
Meeting Date |
09-Jun-2020 |
| Record Date |
13-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Michael F. Cola |
For |
For |
|
2 |
Jeffrey M. Jonas, M.D. |
For |
For |
| 2. |
To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 3. |
To hold a non-binding advisory vote to approve the compensation paid to our named executive officers. |
Management |
For |
For |
Field: Page; Sequence: 54
Field: /Page
SANGAMO THERAPEUTICS, INC.
| Security |
800677106 |
Meeting Type |
Annual |
| Ticker Symbol |
SGMO |
Meeting Date |
18-May-2020 |
| Record Date |
20-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1.1 |
Election of Director: Robert F. Carey |
Management |
For |
For |
| 1.2 |
Election of Director: Stephen G. Dilly, M.B.B.S., Ph.D. |
Management |
For |
For |
| 1.3 |
Election of Director: Alexander D. Macrae, M.B., Ch.B., Ph.D. |
Management |
For |
For |
| 1.4 |
Election of Director: John H. Markels, Ph.D. |
Management |
For |
For |
| 1.5 |
Election of Director: James R. Meyers |
Management |
For |
For |
| 1.6 |
Election of Director: H. Stewart Parker |
Management |
For |
For |
| 1.7 |
Election of Director: Saira Ramasastry |
Management |
For |
For |
| 1.8 |
Election of Director: Karen L. Smith M.D., Ph.D., M.B.A., L.L.M. |
Management |
For |
For |
| 1.9 |
Election of Director: Joseph S. Zakrzewski |
Management |
For |
For |
| 2. |
To approve, on an advisory basis, the compensation of our named executive officers, as described in the accompanying proxy statement |
Management |
For |
For |
| 3. |
To approve the amendment and restatement of the Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan, or the 2018 Plan, to, among other things, increase the aggregate number of shares of our common stock reserved for issuance under the 2018 Plan by 9,900,000 shares |
Management |
For |
For |
| 4. |
To approve an amendment to our Seventh Amended and Restated Certificate of Incorporation, as amended, to increase the total number of shares of our common stock authorized for issuance from 160,000,000 shares to 320,000,000 shares |
Management |
For |
For |
| 5. |
To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2020 |
Management |
For |
For |
Field: Page; Sequence: 55
Field: /Page
SANOFI
| Security |
80105N105 |
Meeting Type |
Annual |
| Ticker Symbol |
SNY |
Meeting Date |
28-Apr-2020 |
| Record Date |
30-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
Approval of the individual company financial statements for the year ended December 31, 2019 |
Management |
For |
For |
| 2. |
Approval of the consolidated financial statements for the year ended December 31, 2019 |
Management |
For |
For |
| 3. |
Appropriation of results for the year ended December 31, 2019 and declaration of dividend |
Management |
For |
For |
| 4. |
Approval of regulated agreements and commitments falling within the scope of Articles L. 225-38 et seq of the French Commercial Code |
Management |
For |
For |
| 5. |
Ratification of the co-opting of Paul Hudson as a Director |
Management |
For |
For |
| 6. |
Reappointment of Laurent Attal as a Director |
Management |
For |
For |
| 7. |
Reappointment of Carole Piwnica as a Director |
Management |
For |
For |
| 8. |
Reappointment of Diane Souza as a Director |
Management |
For |
For |
| 9. |
Reappointment of Thomas Südhof as a Director |
Management |
For |
For |
| 10. |
Appointment of Rachel Duan as a Director |
Management |
For |
For |
| 11. |
Appointment of Lise Kingo as a Director |
Management |
For |
For |
| 12. |
Determination of the compensation amount for the Board of Directors |
Management |
For |
For |
| 13. |
Approval of the compensation policy for directors |
Management |
For |
For |
| 14. |
Approval of the compensation policy for the Chairman of the Board of Directors |
Management |
For |
For |
| 15. |
Approval of the compensation policy for the Chief Executive Officer |
Management |
For |
For |
| 16. |
Approval of the report on the compensation of corporate officers issued in accordance with Article L. 225-37-3 I. of the French Commercial Code |
Management |
For |
For |
| 17. |
Approval of the components of the compensation paid or awarded in respect of the year ended 31 December 2019 to Serge Weinberg, Chairman of the Board |
Management |
For |
For |
| 18. |
Approval of the components of the compensation paid or awarded in respect of the year ended 31 December 2019 to Paul Hudson, Chief Executive Officer from September 1, 2019 |
Management |
For |
For |
| 19. |
Approval of the components of the compensation paid or awarded in respect of the year ended 31 December 2019 to Olivier Brandicourt, Chief Executive Officer until August 31, 2019 |
Management |
For |
For |
| 20. |
Authorization to the Board of Directors to carry out transactions in the Company's shares (usable outside the period of a public tender offer) |
Management |
For |
For |
| 21. |
Powers for formalities |
Management |
For |
For |
Field: Page; Sequence: 56
Field: /Page
Field: Split-Segment; Name: 5
SAREPTA THERAPEUTICS INC.
| Security |
803607100 |
Meeting Type |
Annual |
| Ticker Symbol |
SRPT |
Meeting Date |
04-Jun-2020 |
| Record Date |
13-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1.1 |
Election of Director: Douglas S. Ingram |
Management |
For |
For |
| 1.2 |
Election of Director: Hans Wigzell, M.D., Ph.D. |
Management |
For |
For |
| 1.3 |
Election of Director: Mary Ann Gray, Ph.D. |
Management |
For |
For |
| 2. |
ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATION |
Management |
For |
For |
| 3. |
APPROVAL OF AN AMENDMENT TO THE COMPANY'S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 99,000,000 TO 198,000,000 SHARES |
Management |
For |
For |
| 4. |
APPROVAL OF AN AMENDMENT TO THE COMPANY'S 2018 EQUITY INCENTIVE PLAN TO INCREASE THE MAXIMUM AGGREGATE NUMBER OF SHARES OF COMMON STOCK THAT MAY BE ISSUED PURSUANT TO AWARDS GRANTED UNDER THE 2018 EQUITY INCENTIVE PLAN BY 3,800,000 SHARES TO 8,187,596 SHARES |
Management |
For |
For |
| 5. |
RATIFICATION OF KPMG LLP AS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2020 |
Management |
For |
For |
SEATTLE GENETICS, INC.
| Security |
812578102 |
Meeting Type |
Annual |
| Ticker Symbol |
SGEN |
Meeting Date |
15-May-2020 |
| Record Date |
19-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1.1 |
Election of Class I Director: David W. Gryska |
Management |
For |
For |
| 1.2 |
Election of Class I Director: John A. Orwin |
Management |
For |
For |
| 1.3 |
Election of Class I Director: Alpna H. Seth |
Management |
For |
For |
| 2. |
Approve, on an advisory basis, the compensation of Seattle Genetics' named executive officers as disclosed in the accompanying proxy statement. |
Management |
For |
For |
| 3. |
Approve the amendment and restatement of the Seattle Genetics, Inc. Amended and Restated 2007 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance thereunder by 6,000,000 shares. |
Management |
For |
For |
| 4. |
Ratify the appointment of PricewaterhouseCoopers LLP as Seattle Genetics' independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
Field: Page; Sequence: 57
Field: /Page
SPECTRUM PHARMACEUTICALS, INC.
| Security |
84763A108 |
Meeting Type |
Annual |
| Ticker Symbol |
SPPI |
Meeting Date |
18-Jun-2020 |
| Record Date |
21-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1.1 |
Election of Director: William L. Ashton |
Management |
For |
For |
| 1.2 |
Election of Director: Elizabeth A. Czerepak |
Management |
For |
For |
| 1.3 |
Election of Director: Seth H.Z. Fischer |
Management |
For |
For |
| 1.4 |
Election of Director: Joseph W. Turgeon |
Management |
For |
For |
| 1.5 |
Election of Director: Jeffrey L. Vacirca |
Management |
For |
For |
| 1.6 |
Election of Director: Dolatrai M. Vyas |
Management |
For |
For |
| 1.7 |
Election of Director: Bernice R. Welles |
Management |
For |
For |
| 2. |
To approve, on a non-binding advisory basis, the compensation of our named executive officers, as disclosed in the Compensation Discussion and Analysis section of the Proxy Statement. |
Management |
For |
For |
| 3. |
To approve the Amendment to the Spectrum Pharmaceuticals, Inc. 2018 Long-Term Incentive Plan. |
Management |
For |
For |
| 4. |
To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
STRYKER CORPORATION
| Security |
863667101 |
Meeting Type |
Annual |
| Ticker Symbol |
SYK |
Meeting Date |
05-May-2020 |
| Record Date |
06-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Mary K. Brainerd |
Management |
For |
For |
| 1B. |
Election of Director: Srikant M. Datar, Ph.D. |
Management |
For |
For |
| 1C. |
Election of Director: Roch Doliveux, DVM |
Management |
For |
For |
| 1D. |
Election of Director: Allan C. Golston(Lead Independent Director) |
Management |
For |
For |
| 1E. |
Election of Director: Kevin A. Lobo(Chairman of the Board) |
Management |
For |
For |
| 1F. |
Election of Director: Sherilyn S. McCoy |
Management |
For |
For |
| 1G. |
Election of Director: Andrew K. Silvernail |
Management |
For |
For |
| 1H. |
Election of Director: Lisa M. Skeete Tatum |
Management |
For |
For |
| 1I. |
Election of Director: Ronda E. Stryker |
Management |
For |
For |
| 1J. |
Election of Director: Rajeev Suri |
Management |
For |
For |
| 2. |
Ratify appointment of Ernst & Young LLP as our independent registered public accounting firm for 2020. |
Management |
For |
For |
| 3. |
Advisory vote to approve named executive officer compensation. |
Management |
For |
For |
| 4. |
Non-management employee representation on the Board of Directors. |
Management |
Against |
For |
Field: Page; Sequence: 58
Field: /Page
SUTRO BIOPHARMA, INC.
| Security |
869367102 |
Meeting Type |
Annual |
| Ticker Symbol |
STRO |
Meeting Date |
05-Jun-2020 |
| Record Date |
13-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
William J. Newell |
For |
For |
|
2 |
Connie Matsui |
For |
For |
|
3 |
James Panek |
For |
For |
| 2. |
To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
SYNEOS HEALTH, INC.
| Security |
87166B102 |
Meeting Type |
Annual |
| Ticker Symbol |
SYNH |
Meeting Date |
27-May-2020 |
| Record Date |
30-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Bernadette M. Connaughton |
Management |
For |
For |
| 1B. |
Election of Director: Kenneth F. Meyers |
Management |
For |
For |
| 1C. |
Election of Director: Matthew E. Monaghan |
Management |
For |
For |
| 1D. |
Election of Director: Joshua M. Nelson |
Management |
For |
For |
| 2. |
To approve on an advisory (nonbinding) basis our executive compensation. |
Management |
For |
For |
| 3. |
To ratify the appointment of the Company's independent auditors Deloitte & Touche LLP. |
Management |
For |
For |
TETRAPHASE PHARMACEUTICALS, INC.
| Security |
88165N105 |
Meeting Type |
Special |
| Ticker Symbol |
TTPH |
Meeting Date |
25-Sep-2019 |
| Record Date |
01-Aug-2019 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
To approve an amendment to our certificate of incorporation to effect a reverse stock split at a ratio of not less than 1-for-5 and not greater than 1-for-20, with the exact ratio to be set within that range at the discretion of our board of directors prior to our 2020 annual meeting of stockholders without further approval or authorization of our stockholders and with our board of directors able to elect to abandon such proposed amendment and not effect the reverse stock split authorized by stockholders, in its sole discretion. |
Management |
For |
For |
Field: Page; Sequence: 59
Field: /Page
TETRAPHASE PHARMACEUTICALS, INC.
| Security |
88165N204 |
Meeting Type |
Special |
| Ticker Symbol |
TTPH |
Meeting Date |
08-Jun-2020 |
| Record Date |
22-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
To adopt the Agreement and Plan of Merger, dated as of March 15, 2020 (as it may be amended from time to time), by and among AcelRx Pharmaceuticals, Inc., ("AcelRx"), Tetraphase Pharmaceuticals, Inc., a Delaware corporation ("Tetraphase"), and Consolidation Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of AcelRx ("Merger Sub"), pursuant to which Merger Sub will merge with and into Tetraphase, with Tetraphase as the surviving corporation and an indirect wholly owned subsidiary of AcelRx (the "Merger"). |
Management |
For |
For |
| 2. |
To approve, on a nonbinding advisory basis, "golden parachute" compensation payments that may be payable to Tetraphase's named executive officers in connection with the Merger. |
Management |
For |
For |
| 3. |
To approve the adjournment of the Special Meeting of Tetraphase Pharmaceuticals, Inc. (the "Special Meeting") to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to approve Proposal 1 or to ensure that any supplement or amendment to the proxy statement/prospectus is timely provided to Tetraphase stockholders. |
Management |
For |
For |
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
| Security |
881624209 |
Meeting Type |
Annual |
| Ticker Symbol |
TEVA |
Meeting Date |
09-Jun-2020 |
| Record Date |
09-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Dr. Sol J. Barer |
Management |
For |
For |
| 1B. |
Election of Director: Jean-Michel Halfon |
Management |
For |
For |
| 1C. |
Election of Director: Nechemia (Chemi) J. Peres |
Management |
For |
For |
| 1D. |
Election of Director: Janet S. Vergis |
Management |
For |
For |
| 2. |
To approve, on a non-binding advisory basis, the compensation for Teva's named executive officers. |
Management |
For |
For |
| 3. |
To approve Teva's 2020 Long-Term Equity-Based Incentive Plan, substantially in the form attached as Appendix A to the Proxy Statement. |
Management |
For |
For |
| 4. |
To approve an amendment to the terms of office and employment of Teva's President and Chief Executive Officer. |
Management |
For |
For |
| 5. |
To approve an amendment to Teva's Articles of Association. |
Management |
For |
For |
| 6. |
To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until Teva's 2021 annual meeting of shareholders. |
Management |
For |
For |
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
| Security |
881624209 |
Meeting Type |
Annual |
| Ticker Symbol |
TEVA |
Meeting Date |
09-Jun-2020 |
| Record Date |
30-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Dr. Sol J. Barer |
Management |
For |
For |
| 1B. |
Election of Director: Jean-Michel Halfon |
Management |
For |
For |
| 1C. |
Election of Director: Nechemia (Chemi) J. Peres |
Management |
For |
For |
| 1D. |
Election of Director: Janet S. Vergis |
Management |
For |
For |
| 2. |
To approve, on a non-binding advisory basis, the compensation for Teva's named executive officers. |
Management |
For |
For |
| 3. |
To approve Teva's 2020 Long-Term Equity-Based Incentive Plan, substantially in the form attached as Appendix A to the Proxy Statement. |
Management |
For |
For |
| 4. |
To approve an amendment to the terms of office and employment of Teva's President and Chief Executive Officer. |
Management |
For |
For |
| 5. |
To approve an amendment to Teva's Articles of Association. |
Management |
For |
For |
| 6. |
To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until Teva's 2021 annual meeting of shareholders. |
Management |
For |
For |
Field: Page; Sequence: 60
Field: /Page
THERAVANCE BIOPHARMA, INC.
| Security |
G8807B106 |
Meeting Type |
Annual |
| Ticker Symbol |
TBPH |
Meeting Date |
28-Apr-2020 |
| Record Date |
02-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1.1 |
Election of Director: Dean J. Mitchell |
Management |
For |
For |
| 1.2 |
Election of Director: George M. Whitesides |
Management |
For |
For |
| 1.3 |
Election of Director: William D. Young |
Management |
For |
For |
| 2. |
Ratify the appointment of Ernst & Young LLP as Theravance Biopharma, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 3. |
Approve a non-binding advisory resolution regarding executive compensation. |
Management |
For |
For |
THERMO FISHER SCIENTIFIC INC.
| Security |
883556102 |
Meeting Type |
Annual |
| Ticker Symbol |
TMO |
Meeting Date |
20-May-2020 |
| Record Date |
27-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Marc N. Casper |
Management |
For |
For |
| 1B. |
Election of Director: Nelson J. Chai |
Management |
For |
For |
| 1C. |
Election of Director: C. Martin Harris |
Management |
For |
For |
| 1D. |
Election of Director: Tyler Jacks |
Management |
For |
For |
| 1E. |
Election of Director: Judy C. Lewent |
Management |
For |
For |
| 1F. |
Election of Director: Thomas J. Lynch |
Management |
For |
For |
| 1G. |
Election of Director: Jim P. Manzi |
Management |
For |
For |
| 1H. |
Election of Director: James C. Mullen |
Management |
For |
For |
| 1I. |
Election of Director: Lars R. Sørensen |
Management |
For |
For |
| 1J. |
Election of Director: Debora L. Spar |
Management |
For |
For |
| 1K. |
Election of Director: Scott M. Sperling |
Management |
For |
For |
| 1L. |
Election of Director: Dion J. Weisler |
Management |
For |
For |
| 2. |
An advisory vote to approve named executive officer compensation. |
Management |
For |
For |
| 3. |
Ratification of the Audit Committee's selection of PricewaterhouseCoopers LLP as the Company's independent auditors for 2020. |
Management |
For |
For |
Field: Page; Sequence: 61
Field: /Page
TRILLIUM THERAPEUTICS INC.
| Security |
89620X506 |
Meeting Type |
Annual and Special Meeting |
| Ticker Symbol |
TRIL |
Meeting Date |
30-Jun-2020 |
| Record Date |
15-May-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1 |
DIRECTOR |
Management |
|
|
|
1 |
Mr. Luke Beshar |
For |
For |
|
2 |
Dr. Robert Kirkman |
For |
For |
|
3 |
Mr. Paul Walker |
For |
For |
|
4 |
Dr. Thomas Reynolds |
For |
For |
|
5 |
Dr. Jan Skvarka |
For |
For |
|
6 |
Dr. Helen Tayton-Martin |
For |
For |
| 2 |
To reappoint Ernst & Young, LLP, Chartered Professional Accountants, Licensed Public Accountants, as auditors of the Corporation for the ensuing year and to authorize the directors to fix the remuneration to be paid to the auditors. |
Management |
For |
For |
| 3 |
To consider, and if deemed appropriate, to pass an ordinary resolution of disinterested shareholders, the full text of which is set forth in the Circular, to approve the Corporation's omnibus equity incentive plan. |
Management |
For |
For |
TURNING POINT THERAPEUTICS, INC.
| Security |
90041T108 |
Meeting Type |
Annual |
| Ticker Symbol |
TPTX |
Meeting Date |
15-Jun-2020 |
| Record Date |
20-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Athena Countouriotis MD |
For |
For |
|
2 |
Patrick Machado, J.D. |
For |
For |
|
3 |
Garry Nicholson |
For |
For |
| 2. |
Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2020. |
Management |
For |
For |
Field: Page; Sequence: 62
Field: /Page
ULTRAGENYX PHARMACEUTICAL INC.
| Security |
90400D108 |
Meeting Type |
Annual |
| Ticker Symbol |
RARE |
Meeting Date |
26-Jun-2020 |
| Record Date |
27-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Emil D. Kakkis, M.D., Ph.D. |
Management |
For |
For |
| 1B. |
Election of Director: Shehnaaz Suliman, M.D. |
Management |
For |
For |
| 1C. |
Election of Director: Daniel G. Welch |
Management |
For |
For |
| 2. |
Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020. |
Management |
For |
For |
| 3. |
Advisory (non-binding) vote to approve the compensation of our named executive officers. |
Management |
For |
For |
UNIQURE N.V.
| Security |
N90064101 |
Meeting Type |
Annual |
| Ticker Symbol |
QURE |
Meeting Date |
17-Jun-2020 |
| Record Date |
20-May-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
Resolution to adopt the 2019 annual accounts and treatment of the results. |
Management |
For |
For |
| 2. |
Resolution to discharge liability of the members of the Board for their management. |
Management |
For |
For |
| 3. |
Reappointment of Madhavan Balachandran as non- executive director. |
Management |
For |
For |
| 4. |
Reappointment of Jack Kaye as non-executive director. |
Management |
For |
For |
| 5. |
Reappointment of Jeremy Springhorn as non-executive director. |
Management |
For |
For |
| 6. |
Appointment of Leonard Post as non-executive director. |
Management |
For |
For |
| 7. |
Resolution to reauthorize the Board to issue ordinary shares and options. |
Management |
For |
For |
| 8. |
Resolution to reauthorize the Board to exclude or limit preemptive rights upon the issuance of ordinary shares. |
Management |
For |
For |
| 9. |
Authorization of the Board to repurchase ordinary shares. |
Management |
For |
For |
| 10. |
Resolution to appoint KPMG as external auditor of the Company for the 2020 financial year. |
Management |
For |
For |
| 11. |
Advisory approval of compensation of named executive officers. |
Management |
For |
For |
Field: Page; Sequence: 63
Field: /Page
UNITED THERAPEUTICS CORPORATION
| Security |
91307C102 |
Meeting Type |
Annual |
| Ticker Symbol |
UTHR |
Meeting Date |
26-Jun-2020 |
| Record Date |
30-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Raymond Dwek |
Management |
For |
For |
| 1B. |
Election of Director: Christopher Patusky |
Management |
For |
For |
| 1C. |
Election of Director: Tommy Thompson |
Management |
For |
For |
| 2. |
Approval of an amendment to our Amended and Restated Certificate of Incorporation to declassify our Board of Directors and provide for the annual election of our directors |
Management |
For |
For |
| 3. |
Advisory resolution to approve executive compensation |
Management |
For |
For |
| 4. |
Approval of the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan |
Management |
For |
For |
| 5. |
Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2020 |
Management |
For |
For |
UNITEDHEALTH GROUP INCORPORATED
| Security |
91324P102 |
Meeting Type |
Annual |
| Ticker Symbol |
UNH |
Meeting Date |
01-Jun-2020 |
| Record Date |
07-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Richard T. Burke |
Management |
For |
For |
| 1B. |
Election of Director: Timothy P. Flynn |
Management |
For |
For |
| 1C. |
Election of Director: Stephen J. Hemsley |
Management |
For |
For |
| 1D. |
Election of Director: Michele J. Hooper |
Management |
For |
For |
| 1E. |
Election of Director: F. William McNabb III |
Management |
For |
For |
| 1F. |
Election of Director: Valerie C. Montgomery Rice, M.D. |
Management |
For |
For |
| 1G. |
Election of Director: John H. Noseworthy, M.D. |
Management |
For |
For |
| 1H. |
Election of Director: Glenn M. Renwick |
Management |
For |
For |
| 1I. |
Election of Director: David S. Wichmann |
Management |
For |
For |
| 1J. |
Election of Director: Gail R. Wilensky, Ph.D. |
Management |
For |
For |
| 2. |
Advisory approval of the Company's executive compensation. |
Management |
For |
For |
| 3. |
Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2020. |
Management |
For |
For |
| 4. |
Approval of the UnitedHealth Group 2020 Stock Incentive Plan. |
Management |
For |
For |
| 5. |
If properly presented at the 2020 Annual Meeting of Shareholders, the shareholder proposal set forth in the proxy statement requesting any material amendment to the Company's Bylaws be subject to a non-binding shareholder vote. |
Shareholder |
Against |
For |
Field: Page; Sequence: 64
Field: /Page
VECTIVEBIO HOLDING AG
| Security |
N/A |
Meeting Type |
Written Consent |
| Ticker Symbol |
N/A |
Meeting Date |
19-Dec-2019 |
| Record Date |
N/A |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
Approval of Bridge Loan |
Management |
For |
For |
| 2. |
Amendment to Glypharma purchase agreement |
Management |
For |
For |
VECTIVEBIO HOLDING AG
| Security |
N/A |
Meeting Type |
Extraordinary General Meeting |
| Ticker Symbol |
N/A |
Meeting Date |
6-Jan-2020 |
| Record Date |
N/A |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
Election of Naveed Siddiqi as a new member of the board of directors of the company |
Management |
For |
For |
VECTIVEBIO HOLDING AG
| Security |
N/A |
Meeting Type |
Written Consent |
| Ticker Symbol |
N/A |
Meeting Date |
24-Jun-2020 |
| Record Date |
N/A |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1. |
Constitution of the meting and appointment of chair |
Management |
For |
For |
| 2. |
Approval of the financial statements of the Company for the financial year ended December 31, 2019 |
Management |
For |
For |
| 3. |
Approval of the appropriation of the financial result 2019 |
Management |
For |
For |
| 4 |
Approval of granting discharge to the members of the board of directors and officers from liability |
Management |
|
|
| 5 |
Re-election of the board of directors |
Management |
For |
For |
| 6 |
Re-election of the auditors |
Management |
For |
For |
| 4. |
To approve the Arena Pharmaceuticals, Inc. 2020 Long- Term Incentive Plan. |
Management |
For |
For |
| 5. |
To ratify the appointment of KPMG LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2020. |
Management |
For |
For |
Field: Page; Sequence: 65
Field: /Page
VERTEX PHARMACEUTICALS INCORPORATED
| Security |
92532F100 |
Meeting Type |
Annual |
| Ticker Symbol |
VRTX |
Meeting Date |
03-Jun-2020 |
| Record Date |
09-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Sangeeta Bhatia |
Management |
For |
For |
| 1B. |
Election of Director: Lloyd Carney |
Management |
For |
For |
| 1C. |
Election of Director: Alan Garber |
Management |
For |
For |
| 1D. |
Election of Director: Terrence Kearney |
Management |
For |
For |
| 1E. |
Election of Director: Reshma Kewalramani |
Management |
For |
For |
| 1F. |
Election of Director: Yuchun Lee |
Management |
For |
For |
| 1G. |
Election of Director: Jeffrey Leiden |
Management |
For |
For |
| 1H. |
Election of Director: Margaret McGlynn |
Management |
For |
For |
| 1I. |
Election of Director: Diana McKenzie |
Management |
For |
For |
| 1J. |
Election of Director: Bruce Sachs |
Management |
For |
For |
| 2. |
Ratification of Ernst & Young LLP as our independent Registered Public Accounting firm for the year ending December 31, 2020. |
Management |
For |
For |
| 3. |
Advisory vote on named executive officer compensation. |
Management |
For |
For |
| 4. |
Shareholder proposal, if properly presented at the meeting, requesting that we prepare a report on our policies and activities with respect to lobbying. |
Shareholder |
Against |
For |
WAVE LIFE SCIENCES LTD.
| Security |
Y95308105 |
Meeting Type |
Annual |
| Ticker Symbol |
WVE |
Meeting Date |
08-Aug-2019 |
| Record Date |
17-Jun-2019 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1a. |
Election of Director: Paul B. Bolno, M.D., MBA |
Management |
For |
For |
| 1b. |
Election of Director: Christian Henry |
Management |
For |
For |
| 1c. |
Election of Director: Peter Kolchinsky, Ph.D. |
Management |
For |
For |
| 1d. |
Election of Director: Koji Miura |
Management |
For |
For |
| 1e. |
Election of Director: Adrian Rawcliffe |
Management |
For |
For |
| 1f. |
Election of Director: Ken Takanashi |
Management |
For |
For |
| 1g. |
Election of Director: Gregory L. Verdine, Ph.D. |
Management |
For |
For |
| 2. |
To approve the re-appointment of KPMG LLP to serve as our independent registered public accounting firm and independent Singapore auditor for the year ending December 31, 2019, and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP's remuneration for services provided through the date of our 2020 Annual General Meeting of Shareholders |
Management |
For |
For |
| 3. |
To approve the Company's payment of cash and equity- based compensation to non-employee directors for service on the Board of Directors and its committees, in the manner and on the basis set forth under "Proposal 3: Non-Employee Directors' Compensation" |
Management |
For |
For |
| 4. |
To authorize the Board of Directors to allot and issue Ordinary Shares of Wave Life Sciences Ltd. |
Management |
For |
For |
| 5. |
To approve the Company's 2019 Employee Share Purchase Plan |
Management |
For |
For |
| 6. |
To approve by a non-binding advisory vote the compensation of our named executive officers as disclosed in the proxy statement |
Management |
For |
For |
| 7. |
To approve by a non-binding advisory vote the frequency of holding future advisory votes on the compensation of our named executive officers |
Management |
1 Year |
For |
Field: Page; Sequence: 66
Field: /Page
XENCOR, INC.
| Security |
98401F105 |
Meeting Type |
Annual |
| Ticker Symbol |
XNCR |
Meeting Date |
25-Jun-2020 |
| Record Date |
27-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
Bassil I. Dahiyat |
For |
For |
|
2 |
Ellen G. Feigal |
For |
For |
|
3 |
Kevin C. Gorman |
For |
For |
|
4 |
Kurt A. Gustafson |
For |
For |
|
5 |
Yujiro S. Hata |
For |
For |
|
6 |
A. Bruce Montgomery |
For |
For |
|
7 |
Richard J. Ranieri |
For |
For |
|
8 |
Dagmar Rosa-Bjorkeson |
For |
For |
| 2. |
Proposal to ratify RSM US LLP as the independent registered public accounting firm for 2020 |
Management |
For |
For |
| 3. |
Proposal to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy materials |
Management |
For |
For |
Y-MABS THERAPEUTICS, INC.
| Security |
984241109 |
Meeting Type |
Annual |
| Ticker Symbol |
YMAB |
Meeting Date |
11-Jun-2020 |
| Record Date |
17-Apr-2020 |
|
|
| Item |
Proposal |
|
Vote |
For/Against Management |
| 1. |
DIRECTOR |
Management |
|
|
|
1 |
James I. Healy, M.D. |
For |
For |
|
2 |
Ashutosh Tyagi, M.D. |
For |
For |
|
3 |
Laura J. Hamill |
For |
For |
| 2. |
Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2020 |
Management |
For |
For |
ZIMMER BIOMET HOLDINGS, INC.
| Security |
98956P102 |
Meeting Type |
Annual |
| Ticker Symbol |
ZBH |
Meeting Date |
08-May-2020 |
| Record Date |
09-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Christopher B. Begley |
Management |
For |
For |
| 1B. |
Election of Director: Betsy J. Bernard |
Management |
For |
For |
| 1C. |
Election of Director: Gail K. Boudreaux |
Management |
For |
For |
| 1D. |
Election of Director: Michael J. Farrell |
Management |
For |
For |
| 1E. |
Election of Director: Larry C. Glasscock |
Management |
For |
For |
| 1F. |
Election of Director: Robert A. Hagemann |
Management |
For |
For |
| 1G. |
Election of Director: Bryan C. Hanson |
Management |
For |
For |
| 1H. |
Election of Director: Arthur J. Higgins |
Management |
For |
For |
| 1I. |
Election of Director: Maria Teresa Hilado |
Management |
For |
For |
| 1J. |
Election of Director: Syed Jafry |
Management |
For |
For |
| 1K. |
Election of Director: Michael W. Michelson |
Management |
For |
For |
| 2. |
Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2020. |
Management |
For |
For |
| 3. |
Advisory vote to approve named executive officer compensation (Say on Pay). |
Management |
For |
For |
ZOETIS INC.
| Security |
98978V103 |
Meeting Type |
Annual |
| Ticker Symbol |
ZTS |
Meeting Date |
20-May-2020 |
| Record Date |
26-Mar-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Gregory Norden |
Management |
For |
For |
| 1B. |
Election of Director: Louise M. Parent |
Management |
For |
For |
| 1C. |
Election of Director: Kristin C. Peck |
Management |
For |
For |
| 1D. |
Election of Director: Robert W. Scully |
Management |
For |
For |
| 2. |
Advisory vote to approve our executive compensation (Say on Pay). |
Management |
For |
For |
| 3. |
Advisory vote on the frequency of future advisory votes on executive compensation (Say on Pay frequency). |
Management |
1 Year |
For |
| 4. |
Ratification of appointment of KPMG LLP as our independent registered public accounting firm for 2020. |
Management |
For |
For |
ZOGENIX, INC.
| Security |
98978L204 |
Meeting Type |
Annual |
| Ticker Symbol |
ZGNX |
Meeting Date |
29-May-2020 |
| Record Date |
09-Apr-2020 |
|
|
| Item |
Proposal |
Proposed by |
Vote |
For/Against Management |
| 1A. |
Election of Director: Louis C. Bock |
Management |
For |
For |
| 1B. |
Election of Director: Cam L. Garner |
Management |
For |
For |
| 1C. |
Election of Director: Mark Wiggins |
Management |
For |
For |
| 2. |
Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2020. |
Management |
For |
For |
| 3. |
Approval, on an advisory basis, of the compensation of the named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission. |
Management |
For |
For |
| 4. |
To approve an amendment and restatement of the Zogenix, Inc. 2010 Employee Stock Purchase Plan. |
Management |
For |
For |
Field: Page; Sequence: 67
Field: /Page
SIGNATURES
Pursuant to the requirements of the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| (Registrant) |
Tekla Healthcare Investors |
| By (Signature and Title)* |
|
|
/s/ Daniel R. Omstead |
|
(Daniel R. Omstead, President) |
| Date |
8/17/20 |
Field: Rule-Page
Field: /Rule-Page
*Print the name and title of each signing officer under his or her signature.
Field: Page; Sequence: 68; Options: Last
Field: /Page